
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancers (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Cancers (Basel)</journal-id><journal-id journal-id-type="publisher-id">cancers</journal-id><journal-title-group><journal-title>Cancers</journal-title></journal-title-group><issn pub-type="epub">2072-6694</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3875944</article-id><article-id pub-id-type="pmid">24202450</article-id><article-id pub-id-type="doi">10.3390/cancers5041379</article-id><article-id pub-id-type="publisher-id">cancers-05-01379</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Immune-Checkpoint Blockade and Active Immunotherapy for Glioma </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ahn</surname><given-names>Brian J.</given-names></name><xref ref-type="aff" rid="af1-cancers-05-01379">1</xref><xref ref-type="aff" rid="af2-cancers-05-01379">2</xref></contrib><contrib contrib-type="author"><name><surname>Pollack</surname><given-names>Ian F.</given-names></name><xref ref-type="aff" rid="af2-cancers-05-01379">2</xref><xref ref-type="aff" rid="af3-cancers-05-01379">3</xref></contrib><contrib contrib-type="author"><name><surname>Okada</surname><given-names>Hideho</given-names></name><xref ref-type="aff" rid="af1-cancers-05-01379">1</xref><xref ref-type="aff" rid="af2-cancers-05-01379">2</xref><xref ref-type="aff" rid="af3-cancers-05-01379">3</xref><xref ref-type="aff" rid="af4-cancers-05-01379">4</xref><xref rid="c1-cancers-05-01379" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-cancers-05-01379"><label>1</label>Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA; E-Mail: <email>bra14@pitt.edu</email></aff><aff id="af2-cancers-05-01379"><label>2</label>Brain Tumor Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA; E-Mail: <email>Ian.Pollack@chp.edu</email></aff><aff id="af3-cancers-05-01379"><label>3</label>Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA</aff><aff id="af4-cancers-05-01379"><label>4</label>Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA</aff><author-notes><corresp id="c1-cancers-05-01379"><label>*</label> Author to whom correspondence should be addressed; E-Mail: <email>okadah@upmc.edu</email>; Tel.: +1-412-623-3111; Fax: +1-412-623-1415.</corresp></author-notes><pub-date pub-type="epub"><day>01</day><month>11</month><year>2013</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2013</year></pub-date><volume>5</volume><issue>4</issue><fpage>1379</fpage><lpage>1412</lpage><history><date date-type="received"><day>16</day><month>9</month><year>2013</year></date><date date-type="rev-recd"><day>24</day><month>10</month><year>2013</year></date><date date-type="accepted"><day>24</day><month>10</month><year>2013</year></date></history><permissions><copyright-statement>© 2013 by the authors; licensee MDPI, Basel, Switzerland.</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>).</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="1" pm="."><plain>Cancer immunotherapy has made tremendous progress, including promising results in patients with malignant gliomas. </plain></SENT>
<SENT sid="2" pm="."><plain>Nonetheless, the immunological microenvironment of the brain and tumors arising therein is still believed to be suboptimal for sufficient antitumor immune responses for a variety of reasons, including the operation of “immune-checkpoint” mechanisms. </plain></SENT>
<SENT sid="3" pm="."><plain>While these mechanisms prevent autoimmunity in physiological conditions, malignant tumors, including brain tumors, actively employ these mechanisms to evade from immunological attacks. </plain></SENT>
<SENT sid="4" pm="."><plain>Development of agents designed to unblock these checkpoint steps is currently one of the most active areas of cancer research. </plain></SENT>
<SENT sid="5" pm="."><plain>In this review, we summarize recent progresses in the field of brain tumor immunology with particular foci in the area of immune-checkpoint mechanisms and development of active immunotherapy strategies. </plain></SENT>
<SENT sid="6" pm="."><plain>In the last decade, a number of specific monoclonal antibodies designed to block immune-checkpoint mechanisms have been developed and show efficacy in other cancers, such as melanoma. </plain></SENT>
<SENT sid="7" pm="."><plain>On the other hand, active immunotherapy approaches, such as vaccines, have shown encouraging outcomes. </plain></SENT>
<SENT sid="8" pm="."><plain>We believe that development of effective immunotherapy approaches should ultimately integrate those checkpoint-blockade agents to enhance the efficacy of therapeutic approaches. </plain></SENT>
<SENT sid="9" pm="."><plain>With these agents available, it is going to be quite an exciting time in the field. </plain></SENT>
<SENT sid="10" pm="."><plain>The eventual success of immunotherapies for brain tumors will be dependent upon not only an in-depth understanding of immunology behind the brain and brain tumors, but also collaboration and teamwork for the development of novel trials that address multiple layers of immunological challenges in gliomas. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>glioma</kwd><kwd>cancer vaccines</kwd><kwd>tumor immunity</kwd><kwd>T cells</kwd><kwd>tumor microenvironment</kwd><kwd>cancer immunotherapy </kwd></kwd-group></SecTag></article-meta></front><body><SecTag type="INTRO"><sec><title><text><SENT sid="11" pm="."><plain>1. </plain></SENT>
<SENT sid="12" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="13" pm="."><plain>The main premise of cancer immunotherapy is to harness the patient’s own immune system to attack malignant tumor cells. </plain></SENT>
<SENT sid="14" pm="."><plain>This area of research has made tremendous progress, illustrated by the United States Food and Drug Administration (FDA) approval of a monoclonal antibody (mAb), ipilimumab, for treatment of metastatic melanoma [1,2] and a vaccine for prostate cancers as the first vaccine against non-viral cancers [3]. </plain></SENT>
<SENT sid="15" pm="."><plain>For central nervous system (CNS) cancers, early phase immunotherapy trials showed encouraging outcomes. </plain></SENT>
<SENT sid="16" pm="."><plain>Nonetheless, the immunological microenvironment of the CNS and tumors arising in the CNS is still believed to be suboptimal for sufficient antitumor immune responses for a variety of reasons, including the operation of “immune-checkpoint” mechanisms. </plain></SENT>
<SENT sid="17" pm="."><plain>These are mechanisms that inhibit the function of cytotoxic immune responses and induce immunological tolerance. </plain></SENT>
<SENT sid="18" pm="."><plain>While these mechanisms prevent autoimmunity in physiological conditions, malignant tumors, including brain tumors, actively employ these mechanisms to evade from immunological attacks. </plain></SENT>
<SENT sid="19" pm="."><plain>Development of agents designed to unblock these checkpoint steps is currently one of the most active areas of cancer research. </plain></SENT>
<SENT sid="20" pm="."><plain>In this review, we first discuss recent advances in our understanding of drug-development against immune-checkpoint mechanisms. </plain></SENT>
<SENT sid="21" pm="."><plain>We also review advances in active immunotherapy strategies for glioma, with an emphasis on lessons learned from recent clinical trials. </plain></SENT>
</text></p></sec></SecTag><sec><title><text><SENT sid="22" pm="."><plain>2. </plain></SENT>
<SENT sid="23" pm="."><plain>Immunosuppression by Gliomas </plain></SENT>
</text></title><p><text><SENT sid="24" pm="."><plain>The microenvironment of gliomas, including that of glioblastoma (GBM), is known to produce immunosuppressive molecules and recruit immunosuppressive leukocytes. </plain></SENT>
</text></p><sec><title><text><SENT sid="25" pm="."><plain>2.1. </plain></SENT>
<SENT sid="26" pm="."><plain>Immunosuppressive Factors </plain></SENT>
</text></title><p><text><SENT sid="27" pm="."><plain>Gliomas have been shown to synthesize and secrete multiple factors that are capable of inhibiting anti-tumor immune responsiveness [4,5]. </plain></SENT>
<SENT sid="28" pm="."><plain>The list of these factors have expanded and further characterized over the last several years. </plain></SENT>
<SENT sid="29" pm="."><plain>It is also important to develop strategies to block the function of these molecules, thereby promoting anti-tumor immune responses. </plain></SENT>
<SENT sid="30" pm="."><plain>In this section, we update and summarize each of these factors that appear to be relevant to gliomas. </plain></SENT>
</text></p><sec><title><text><SENT sid="31" pm="."><plain>2.1.1. </plain></SENT>
<SENT sid="32" pm="."><plain>Transforming Growth Factor β (TGF-β) </plain></SENT>
</text></title><p><text><SENT sid="33" pm="."><plain>TGF-β is one of the most potent immunosuppressive cytokines; its biological effects are multiple and complex [6]. </plain></SENT>
<SENT sid="34" pm="."><plain>Specifically, for immune cells, they include the inhibition of (1) antigen-presenting cell (APC) maturation (2) functions of APCs, (3) T-cell activation, and (4) their differentiation towards effector cells. </plain></SENT>
<SENT sid="35" pm="."><plain>Recent studies have shown that TGF-β is up-regulated in glioma cell subpopulations that are resistant to the cytotoxic effects of allogeneic cytotoxic T-cells (CTLs) [7,8]. </plain></SENT>
</text></p><p><text><SENT sid="36" pm="."><plain>TGF-β can abrogate immune rejection by inhibiting natural killer (NK) cells function. </plain></SENT>
<SENT sid="37" pm="."><plain>NKG2D is an NK-cell activating receptor, but GBM exhibited decreased NKG2D-mediated tumor recognition and lysis due to TGF-β promoted down-regulation of NKG2D ligands on glioma cells [9] and NKG2D on NK and T cells [10]. </plain></SENT>
<SENT sid="38" pm="."><plain>Inhibition of TGF-β by interfering RNA [11] or soluble TGF-β receptor [12,13] resulted in improved NKG2D-mediated immune response and prolonged survival in mouse models. </plain></SENT>
</text></p><p><text><SENT sid="39" pm="."><plain>TGF-β inhibition can potentially bolster vaccine efficacy for more robust anti-tumor immune surveillance. </plain></SENT>
<SENT sid="40" pm="."><plain>Both TGF-β anti-sense oligonucleotides [14] and systemic blockade of TGF-β by specific monoclonal antibody (mAb) [8] enhanced the efficacy of glioma-specific vaccines and improved survival. </plain></SENT>
<SENT sid="41" pm="."><plain>Although in both studies, blockade of TGF-β alone had no significant impacts on prolonging the survival of glioma-bearing mice. </plain></SENT>
</text></p><p><text><SENT sid="42" pm="."><plain>In addition to immune cells, TGF-β can have direct effects on glioma cells and glioma stem cell populations, and can promote tumor development independent of immune suppression. </plain></SENT>
<SENT sid="43" pm="."><plain>Recent studies have examined the impact of TGF-β on glioma-initiating cells (GIC). </plain></SENT>
<SENT sid="44" pm="."><plain>Targeting TGF-β receptors may specifically target GIC [15], where TGF-β signaling has been linked with tumor propagating properties of GIC, such as invasion [16], radiation resistance [17], self-renewal [18], and tumorogenecity [19]. </plain></SENT>
</text></p><p><text><SENT sid="45" pm="."><plain>A recent study demonstrated that TGF-β stimulation induces microRNA-182 expression, thereby aberrantly activating NF-κB signaling in GBM cells [20], clarifying a critical point of cross-talk between molecular signaling pathways. </plain></SENT>
<SENT sid="46" pm="."><plain>These findings provide a greater understanding of the complex interplay between signaling pathways in cancer that may ultimately prove useful in the development of synergistic targeting approaches. </plain></SENT>
</text></p><p><text><SENT sid="47" pm="."><plain>Preclinical data suggest TGF-β inhibition as an attractive target for treatment of human gliomas for its diverse effects on multiple cell types, which culminate in promoting glioma development. </plain></SENT>
<SENT sid="48" pm="."><plain>TGF-β-targeting antisense oligonucleotides showed improved survival compared to historical controls of recurrent and refractory high-grade glioma in phase I/II, but the phase III trials were terminated due to the inclusion of temozolomide (TMZ) in the standard-of-care in GBM therapy and resulting lack of patient accrual. </plain></SENT>
<SENT sid="49" pm="."><plain>Currently, investigations into oral TGF-β receptor 1 inhibitors and TGF-β blocking antibody are underway in phase II trials [21]. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="50" pm="."><plain>2.1.2. </plain></SENT>
<SENT sid="51" pm="."><plain>Interleukin 10 (IL-10) </plain></SENT>
</text></title><p><text><SENT sid="52" pm="."><plain>IL-10 is primarily produced by monocytes and, to a lesser extent, type 2 T helper (Th2) lymphocytes, mastocytes, regulatory T cells (Tregs), and in a certain subset of activated T cells and B cells [22]. </plain></SENT>
<SENT sid="53" pm="."><plain>IL-10 can be produced by monocytes upon programmed death (PD)-1 triggering in these cells [23]. </plain></SENT>
<SENT sid="54" pm="."><plain>Like TGF-β, this cytokine has pleiotropic effects in immunoregulation and inflammation. </plain></SENT>
<SENT sid="55" pm="."><plain>IL-10 down-regulates the expression of Th1 cytokines, MHC class II antigens, and costimulatory molecules on APCs. </plain></SENT>
<SENT sid="56" pm="."><plain>The expression levels of IL-10 in glioma tissue correlate with glioma grade as well as a degree of brain invasiveness [24,25]. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="57" pm="."><plain>2.1.3. </plain></SENT>
<SENT sid="58" pm="."><plain>Prostaglandin E2 (PGE2) </plain></SENT>
</text></title><p><text><SENT sid="59" pm="."><plain>Cyclooxygenase-2 (COX-2) catalyzes the conversion of arachidonic acid to prostaglandins. </plain></SENT>
<SENT sid="60" pm="."><plain>COX-2 and its product PGE2 are known to promote tumor growth, angiogenesis, and invasion of cancer cells [26,27]. </plain></SENT>
<SENT sid="61" pm="."><plain>COX-2 and PGE2 also promote immune escape of tumors through a variety of mechanisms, including induction Tregs [28], suppression of T-helper (Th)1 cells [29,30], and recruitment of Th2 cells [31,32,33]. </plain></SENT>
<SENT sid="62" pm="."><plain>PGE2 induces the differentiation of Gr1+CD11b+ myeloid-derived suppressor cells (MDSCs) from bone marrow stem cells [34]. </plain></SENT>
<SENT sid="63" pm="."><plain>Furthermore, PGE2 produced by the tumor induces arginase 1 and cationic amino acid transporter (CAT)-2B in MDSCs, both of which deplete arginine from the tumor microenvironment and impair T-cell function [35,36]. </plain></SENT>
<SENT sid="64" pm="."><plain>We recently demonstrated in our de novo glioma model that treatment with the COX-2 inhibitors acetylsalicylic acid (ASA) or celecoxib inhibited systemic PGE₂ production and delayed glioma development [37]. </plain></SENT>
<SENT sid="65" pm="."><plain>ASA treatment also reduced monocyte chemoattracting protein (MCP)-1, also known as CCL2 (C-C motif ligand 2), in the glioma as well as the number of MDSCs in both bone marrow and the glioma. </plain></SENT>
<SENT sid="66" pm="."><plain>Both ASA-treated and Cox2−/− mice demonstrated a reduction in MDSCs and their CCL2-mediated accumulation in the glioma. </plain></SENT>
<SENT sid="67" pm="."><plain>Conversely, Cox2−/− mice and ASA-treated wild-type mice displayed enhanced expression of CXCL10 (C-X-C motif chemokine 10) and tumor-infiltration of CTLs [37]. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="68" pm="."><plain>2.1.4. </plain></SENT>
<SENT sid="69" pm="."><plain>CCL2 (Also Known as Macrophage Chemoattractive Protein 1; MCP-1) </plain></SENT>
</text></title><p><text><SENT sid="70" pm="."><plain>CCL2 is a chemokine secreted by a variety of glioma cell lines and expressed in GBMs [38,39]. </plain></SENT>
<SENT sid="71" pm="."><plain>In addition to its angiogenetic effects [40], it is associated with recruitment of immunosuppressive leukocytes, such as MDSC and regularory T-cells (Tregs) [37,41,42,43]. </plain></SENT>
<SENT sid="72" pm="."><plain>Systemic blockade of CCL2 exhibited reduced infiltration of MDSC and tumor-associated macrophages (TAM) into the glioma site and prolonged survival in murine models. </plain></SENT>
<SENT sid="73" pm="."><plain>Concurrent chemotherapy with TMZ further enhanced the survival [44]. </plain></SENT>
<SENT sid="74" pm="."><plain>TMZ treatment of GBM cells in vitro demonstrated decreased CCL2 production and subsequently reduced migration of Tregs [42], suggesting a possible additive effect of TMZ and CCL2 blockade strategies. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="75" pm="."><plain>2.1.5. </plain></SENT>
<SENT sid="76" pm="."><plain>Fas Receptor (FasR)/Ligand (FasL) </plain></SENT>
</text></title><p><text><SENT sid="77" pm="."><plain>The Fas receptor is a death receptor on the surface of cells that leads to apoptosis [45,46,47]. </plain></SENT>
<SENT sid="78" pm="."><plain>Malignant gliomas express FasL, which induces apoptotic cell death of FasR-expressing adjacent immune cells infiltrating into tumors [47]. </plain></SENT>
<SENT sid="79" pm="."><plain>In addition, FasR expressed on glioma cells induces proinflammatory and angiogenic mediators, which in turn protect and support tumors growth [48]. </plain></SENT>
</text></p><p><text><SENT sid="80" pm="."><plain>Activation of Fas signaling in tumor cells may represent a possibly efficacious adjuvant to current anti-tumor therapy. </plain></SENT>
<SENT sid="81" pm="."><plain>Most treatments, such as some chemotherapies [49,50], indirectly target this pathway by up-regulating FasR, thereby promoting cell apoptosis. </plain></SENT>
<SENT sid="82" pm="."><plain>Additionally, some success has been demonstrated by directly activating this pathway. </plain></SENT>
<SENT sid="83" pm="."><plain>Treating gliomas with recombinant FasL and concurrent etoposide demonstrated increased tumor cell apoptosis of human GBM cells in vitro and improved symptom-free survival in vivo in mouse xenograft models [51]. </plain></SENT>
<SENT sid="84" pm="."><plain>The effect of FasL on T-cell functioning or apoptosis was not examined in this study, and further studies should examine any collateral effects of exogenous FasL on T-cell function. </plain></SENT>
</text></p><p><text><SENT sid="85" pm="."><plain>FasL knockdown with silencing RNA in rat glioma cell lines exhibited reduced tumor growth and increased CD3 T-cell infiltration in vivo [52]. </plain></SENT>
<SENT sid="86" pm="."><plain>This particular study utilized knock down of FasL in glioma cells prior to transplantation into their mouse model. </plain></SENT>
<SENT sid="87" pm="."><plain>Another examination utilized viral vectors to transduce glioma cells with FasL and Fas-associated death domain (FADD). </plain></SENT>
<SENT sid="88" pm="."><plain>These authors compared transduction efficacy when glioma cells were transduced prior to tumor transplantation (ex vivo transduction) or direct administration of the gene vector into established murine tumors (in vivo transduction), resulting in a 95% and 18% rate of cell transduction, respectively. </plain></SENT>
<SENT sid="89" pm="."><plain>Intracranial implantation of pre-transduced glioma cells resulted in better survival outcome when compared with viral vectors inoculated one week post-implantation of tumor cells, indicating that therapeutic efficacy is dependent on the viral spread and mode of viral vector administration. </plain></SENT>
<SENT sid="90" pm="."><plain>Concurrent treatment with TMZ or radiation therapy exhibited prolonged survival compared to FAS/FADD viral vector alone [53]. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="91" pm="."><plain>2.1.6. </plain></SENT>
<SENT sid="92" pm="."><plain>Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) </plain></SENT>
</text></title><p><text><SENT sid="93" pm="."><plain>CTLA-4 is a homologue of CD28, and expressed primarily on activated lymphocytes, where it competitively binds B7-1 and B7-2 due to its higher affinity for these molecules compared to CD28. </plain></SENT>
<SENT sid="94" pm="."><plain>Signaling through CTLA-4 decreases T cell responsiveness and activation [54]. </plain></SENT>
<SENT sid="95" pm="."><plain>Regulatory T cells constitutively express CTLA-4, where it is thought to play an important role in their suppressive capabilities [55]. </plain></SENT>
</text></p><p><text><SENT sid="96" pm="."><plain>The United States FDA recently approved an anti-CTLA-4 mAb ipilimumab for treatment of metastatic melanoma [1,2]. </plain></SENT>
<SENT sid="97" pm="."><plain>In preclinical mouse glioma models, systemic blockade of CTLA-4 exhibited increased survival [56]. </plain></SENT>
<SENT sid="98" pm="."><plain>This blockade was associated with increased systemic CD4 T cell counts, as well as reduced Treg function but not frequency. </plain></SENT>
<SENT sid="99" pm="."><plain>There was also no induction of CNS related autoimmunity, a major concern for this treatment from trials in other cancer types. </plain></SENT>
<SENT sid="100" pm="."><plain>Additionally, when used in combination with a glioma vaccine of irradiated glioma cell lines expressing granulocyte macrophage-colony stimulating factor (GM-CSF), there was improved survival and increased levels of IFN-γ production compared to treatment with CTLA-4 blocking mAb alone [57]. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="101" pm="."><plain>2.1.7. </plain></SENT>
<SENT sid="102" pm="."><plain>B7-Homologue 1 (B7-H1); Programmed Death Ligand-1 (PD-L1) </plain></SENT>
</text></title><p><text><SENT sid="103" pm="."><plain>The B7 family consists of co-stimulatory molecules that positively and negatively regulate immune responses. </plain></SENT>
<SENT sid="104" pm="."><plain>Among them, B7-homologue 1 (B7-H1), also known as programmed death ligand-1 (PD-L1), exerts immunosuppressive functions when interacting with its receptor PD-1 [58]. </plain></SENT>
<SENT sid="105" pm="."><plain>Glioma cells express B7-H1, which inhibits T-cell functions via suppression of cytokine production levels (IFN-γ, IL-2, and IL-10) and induction of apoptosis in tumor-specific T-cells [59]. </plain></SENT>
<SENT sid="106" pm="."><plain>GBMs often possess mutations in a tumor-suppressor gene, phosphatase and tensin homolog (PTEN), which are associated with up-regulation of B7-H1 [60]. </plain></SENT>
<SENT sid="107" pm="."><plain>Interestingly, IFN-γ treatment potentiated glioma immune evasion in PTEN-deficient glioma cells by promoting B7-H1 expression and T-cell apoptosis [61]. </plain></SENT>
</text></p><p><text><SENT sid="108" pm="."><plain>Targeting the PI3K/mTOR pathway with selective inhibitors was demonstrated to be a potential mechanism of reducing B7-H1 expression and improving T cell function [62]. </plain></SENT>
<SENT sid="109" pm="."><plain>Targeting this pathway with PD-1 blocking antibody was evaluated in conjunction with stereotactic radiotherapy in murine models of intracranial gliomas [63]. </plain></SENT>
<SENT sid="110" pm="."><plain>While the PD-1 blockade alone exhibited only a minimal increase in median survival, the combined therapy with stereotactic radiotherapy demonstrated a more drastic impact compared to either treatment alone. </plain></SENT>
<SENT sid="111" pm="."><plain>This improved survival was associated with increased CD8+ lymphocyte and decreased Treg infiltration into the tumor site. </plain></SENT>
<SENT sid="112" pm="."><plain>Currently, clinical trials are ongoing for multiple refractory and recurrent cancer types utilizing both anti-PD-1 [64] and anti-PD-L1 [65] blocking mAbs, and although early in their investigations, these antibodies are showing promising results. </plain></SENT>
</text></p></sec></sec><sec><title><text><SENT sid="113" pm="."><plain>2.2. </plain></SENT>
<SENT sid="114" pm="."><plain>Immunosuppressive Leukocytes </plain></SENT>
</text></title><p><text><SENT sid="115" pm="."><plain>A large number of observations suggest that certain types of immune cells in the tumor microenvironment (TME) are not innocent bystanders at brain tumor sites, but may actually promote tumor development and progression [66,67,68]. </plain></SENT>
<SENT sid="116" pm="."><plain>MDSCs and Tregs may affect these processes via their ability to express a large variety of factors, including immunoregulatory cytokines and cell surface molecules, which can suppress T-cell activation, proliferation, trafficking and effector function. </plain></SENT>
<SENT sid="117" pm="."><plain>These cytokines may be secreted not only by inflammatory cells, but also by the tumor cells and stroma cells, together establishing a local environment that significantly promotes brain tumor growth. </plain></SENT>
<SENT sid="118" pm="."><plain>These cell types are a potential target for improving efficacy of immunotherapies and prolonging survival of patients with malignant gliomas (Table 1). </plain></SENT>
<SENT sid="119" pm="."><plain>In glioma models and patients, Tregs have been the predominant targets, and research into modulating MDSC populations is still early in its inception for treatment of malignant gliomas. </plain></SENT>
</text></p><sec><title><text><SENT sid="120" pm="."><plain>2.2.1. </plain></SENT>
<SENT sid="121" pm="."><plain>Myeloid-Derived Suppressor Cells (MDSCs) </plain></SENT>
</text></title><p><text><SENT sid="122" pm="."><plain>Expanded populations of immature myeloid cells have been demonstrated in essentially all cancer types [66]. </plain></SENT>
<SENT sid="123" pm="."><plain>Pathological conditions such as cancer can halt normal maturation of these cells, promote expansion of these immature myeloid cells, and induce suppressive effectors [66,69,70]. </plain></SENT>
<SENT sid="124" pm="."><plain>These cells possess immature phenotype and morphology, and can promote tumor development via T-cell suppression dependent and independent mechanisms. </plain></SENT>
</text></p><p><text><SENT sid="125" pm="."><plain>In mice, these immature myeloid cells are routinely identified by the expression of CD11b and Gr1. </plain></SENT>
<SENT sid="126" pm="."><plain>Neutrophilic (G-MDSC) and monocytic (M-MDSC) subtypes can be further stratified by expression of Ly6G and Ly6C, respectively. </plain></SENT>
<SENT sid="127" pm="."><plain>These cells have demonstrated T-cell suppression via various effects such as arginase1 [71], inducible nitric oxide synthase (iNOS) [71], reactive oxygen species (ROS) [72], depletion of cysteine [73], among others. </plain></SENT>
<SENT sid="128" pm="."><plain>They have also been demonstrated to promote tumor angiogenesis, invasion, proliferation, and metastasis. </plain></SENT>
<SENT sid="129" pm="."><plain>In murine models, selective depletion of these cells has shown reduced tumor growth and improved survival [37]. </plain></SENT>
</text></p><p><text><SENT sid="130" pm="."><plain>In human cancers, these cells are identified by expression of CD11b and CD33 and by lack of expression of human leukocyte antigen (HLA)-DR with similar granulocytic and monocytic subtypes, differentiated by expression of CD15 and CD14, respectively [74]. </plain></SENT>
<SENT sid="131" pm="."><plain>The accumulation of these cells and their subtypes, differ depending on the cancer type. </plain></SENT>
<SENT sid="132" pm="."><plain>In a recent phase II study of peptide-based vaccines in HLA-A*02+ patients with advanced renal cell carcinoma, the numbers of CD14+HLA-DR−/low and CD11b+CD14−CD15+ MDSC were significantly negatively associated with overall survival [75]. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="cancers-05-01379-t001" position="float"><object-id pub-id-type="pii">cancers-05-01379-t001_Table 1</object-id><label>Table 1</label><caption><p><text><SENT sid="133" pm="."><plain>Agents targeting immunosuppressive cells. </plain></SENT>
</text></p></caption></table-wrap></SecTag><p><text><SENT sid="134" pm="."><plain>In human GBM, expanded populations of circulating CD15+CD33+HLA-DR− and increased levels of plasma arginase 1 have been observed [90]. </plain></SENT>
<SENT sid="135" pm="."><plain>The impact of these suppressive cells require further elucidation such as their role in limiting anti-tumor immunity at the tumor site and prognostic significance on survival in patients with malignant gliomas. </plain></SENT>
</text></p><p><text><SENT sid="136" pm="."><plain>In our preclinical study, neutralizing mAb against CCL2, a chemokine with MDSC attracting properties, reduced MDSC infiltration into gliomas in mice. </plain></SENT>
<SENT sid="137" pm="."><plain>When administered alone, there was a small but significant increase in survival. </plain></SENT>
<SENT sid="138" pm="."><plain>When used in combination with TMZ treatment, additional improvements in survival were observed compared to TMZ alone [44]. </plain></SENT>
<SENT sid="139" pm="."><plain>Additionally, we also demonstrated direct depletion of MDSC populations with anti-Gr1 antibodies improves survival of murine glioma models [37]. </plain></SENT>
<SENT sid="140" pm="."><plain>Our studies suggest the importance of targeting MDSC in the treatment of malignant gliomas. </plain></SENT>
</text></p><p><text><SENT sid="141" pm="."><plain>Many MDSC modulating agents have been examined as a means to improve efficacy of immunotherapies in many cancer types. </plain></SENT>
<SENT sid="142" pm="."><plain>These agents can be broadly classified depending on their predominant mechanisms for reducing MDSC-mediated suppression into three groups: (1) promoting differentiation of MDSC; (2) decreasing MDSC numbers; (3) reducing MDSC function. </plain></SENT>
<SENT sid="143" pm="."><plain>A more comprehensive review of targeting MDSC in all tumor types can be found in a recent review [91]. </plain></SENT>
<SENT sid="144" pm="."><plain>Many of these therapies have already been examined in treatment of gliomas, but no studies have examined the changes to immune function and the effects on concurrent immunotherapy. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="145" pm="."><plain>2.2.2. </plain></SENT>
<SENT sid="146" pm="."><plain>Inducing Differentiation of MDSC </plain></SENT>
</text></title><p><text><SENT sid="147" pm="."><plain>All-trans retinoic acid [28], a derivative of vitamin A, can promote differentiation of MDSC via glutathione-dependent reduction of ROS [92]. </plain></SENT>
<SENT sid="148" pm="."><plain>Treatment with ATRA reduced MDSC populations, increased functions of Th1 T cell response, and improved immune responses against tumor antigens in patients with small cell lung cancer [93] and similarly in renal cell carcinoma [94]. </plain></SENT>
<SENT sid="149" pm="."><plain>Currently, in glioma, in vitro experiments have demonstrated that ATRA reduced stem cell characteristics such as self-renewal and proliferation [87,88] but its impact on MDSC populations and overall survival remain to be investigated. </plain></SENT>
<SENT sid="150" pm="."><plain>Vitamin D3 has also been demonstrated to promote myeloid progenitor differentiation and reduction of immunosuppression in head and neck squamous cell carcinomas. </plain></SENT>
<SENT sid="151" pm="."><plain>With treatment, patients also exhibited increased plasma IFN-γ levels [95]. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="152" pm="."><plain>2.2.3. </plain></SENT>
<SENT sid="153" pm="."><plain>Reducing MDSC Numbers </plain></SENT>
</text></title><p><text><SENT sid="154" pm="."><plain>Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor. </plain></SENT>
<SENT sid="155" pm="."><plain>Molecular targets for sunitinib include all receptors for platelet-derived growth factor, vascular endothelial growth factor receptors and CD117, all of which play a role in both tumor angiogenesis and tumor cell proliferation [96,97]. </plain></SENT>
<SENT sid="156" pm="."><plain>The simultaneous inhibition of these targets therefore leads to both reduced tumor vascularization and cancer cell death, and ultimately tumor shrinkage. </plain></SENT>
</text></p><p><text><SENT sid="157" pm="."><plain>The evaluation of RCC patients demonstrated that treatment with sunitinib increased type-1 response including IFN-γ induction and reduction of MDSC [98] and Treg populations [99]. </plain></SENT>
<SENT sid="158" pm="."><plain>In murine models, treatment was also associated with decreased immunosuppressive effectors including surface PD-L1 and secretion of IL-10 [100]. </plain></SENT>
<SENT sid="159" pm="."><plain>Sunitinib decreased MDSC by promoting apoptosis of G-MDSC and decreased proliferation of M-MDSC [101]. </plain></SENT>
<SENT sid="160" pm="."><plain>When utilized in combination with immunotherapies including a dendritic cell (DC)-based vaccine [102], IL-12 and 4-IBB [100], or adoptive cell therapy [103], a more robust antitumor immune response, decreased tumor growth, and improved survival were observed in various murine models. </plain></SENT>
</text></p><p><text><SENT sid="161" pm="."><plain>In treatment of glioma, there are conflicting reports of the efficacy of sunitinib in animal models. </plain></SENT>
<SENT sid="162" pm="."><plain>In murine models, sunitinib treatment did not improve survival when in combination with low dose radiotherapy [82] or another tyrosine inhibitor, gefintinib [83], but seemed to improve the efficacy of concurrent TMZ treatment [81]. </plain></SENT>
</text></p><p><text><SENT sid="163" pm="."><plain>The results in independent human clinical trials are also not promising. </plain></SENT>
<SENT sid="164" pm="."><plain>When administered as a single agent in multiple phase 2 trials in patients with malignant gliomas, no improvement was observed in either progression free survival or overall survival [84,85,86]. </plain></SENT>
<SENT sid="165" pm="."><plain>Many of these agents including sunitinib may have better efficacy when used in combination with immunotherapies as discussed earlier. </plain></SENT>
<SENT sid="166" pm="."><plain>The precise effects of sunitinib on MDSC populations in glioma and subsequent effects on immunotherapy remain to be determined. </plain></SENT>
</text></p><p><text><SENT sid="167" pm="."><plain>Other agents including chemotherapies, gemcitabine [104] and 5-flourouracil [105], have also been shown to reduce MDSC populations by induction of apoptosis while preserving T-cell functions. </plain></SENT>
<SENT sid="168" pm="."><plain>They have also demonstrated bolstered efficacy of tumor vaccines; and evaluations in glioma models are warranted. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="169" pm="."><plain>2.2.4. </plain></SENT>
<SENT sid="170" pm="."><plain>Reducing MDSC Function </plain></SENT>
</text></title><p><text><SENT sid="171" pm="."><plain>COX-2 expression and subsequent PGE2 production have been shown to induce immunosuppressive function in MDSC [106]. </plain></SENT>
<SENT sid="172" pm="."><plain>This pathway has been examined by our group in our de novo glioma model. </plain></SENT>
<SENT sid="173" pm="."><plain>Treatment of COX-2 inhibitors alone, including celecoxib can improve survival. </plain></SENT>
<SENT sid="174" pm="."><plain>PGE2 production was associated with increased CCL2, which can attract suppressive myeloid cells to the glioma site. </plain></SENT>
<SENT sid="175" pm="."><plain>Celecoxib treatment reduced CCL2 and increased CXCL10 production, recruiting CTL to the tumor site [37]. </plain></SENT>
<SENT sid="176" pm="."><plain>Similar results were observed in murine models of ovarian cancer, where COX-2 inhibition inhibited CXCR4 expression on MDSC and their responsiveness to CXCL12 [107]. </plain></SENT>
</text></p><p><text><SENT sid="177" pm="."><plain>Additionally, phosphodiesterase-5 (PDE-5) inhibitors, such as sidenafil, have been demonstrated to inhibit the function of MDSCs. </plain></SENT>
<SENT sid="178" pm="."><plain>In murine models of breast and colon cancers, treatment with sidenafil decreased arg1 and iNOS expression, resulting in increased numbers of tumor-infiltrating CD8+ T-cells [108]. </plain></SENT>
<SENT sid="179" pm="."><plain>Furthermore, combination of adoptive therapy with sidenafil therapy delayed tumor growth [108]. In vitro cultures with sidenafil improved T-cell functions in head and neck squamous cell carcinoma [108]. </plain></SENT>
<SENT sid="180" pm="."><plain>Recent reports from melanoma patients corroborate similar findings [109]. </plain></SENT>
<SENT sid="181" pm="."><plain>In glioma treatment, vardanefil, another PDE-5 inhibitor, when used in concert with adriamcyin, improved tumor tissue penetration by adriamcyin and survival [89]. </plain></SENT>
<SENT sid="182" pm="."><plain>The impact of myeloid modulation was not examined as a mediator of the improved survival observed in this study. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="183" pm="."><plain>2.2.5. </plain></SENT>
<SENT sid="184" pm="."><plain>Tumor-Associated Macrophages/Microglia (TAM) </plain></SENT>
</text></title><p><text><SENT sid="185" pm="."><plain>Human glioma exhibit extensive macrophages/microglia infiltrate, which can comprise up to 30% of the inflammatory cells at the tumor site [110]. </plain></SENT>
<SENT sid="186" pm="."><plain>Macrophages can be polarized to cytotoxic M1 or tolerogenic M2 type macrophages, depending upon the type of stimulation [67,111]. </plain></SENT>
<SENT sid="187" pm="."><plain>Lipopolysaccharides (LPS) and IFN-γ induce M1 type polarization, whereas IL-10 and TGF-β polarize them toward M2 type macrophages. </plain></SENT>
<SENT sid="188" pm="."><plain>Tumor-associated macrophages/microglia (TAM) encounter tumor-derived M2-inducing factors, and hence demonstrate M2 phenotype, which promotes tumor growth [67,111]. </plain></SENT>
<SENT sid="189" pm="."><plain>Although the relationship of these TAM to MDSC is not entirely clear, current evidence suggests that MDSC, particularly the LY6C+ monocytic subtype may be a progenitor to TAM, since these cells have been shown to be attracted to the tumor site, where they are induced into TAM-like cells by the tumor microenvironment [66]. </plain></SENT>
<SENT sid="190" pm="."><plain>TAM are enriched at the tumor site by recruitment via growth factors and chemokines including, CCL-2 [44,112,113], stromal-derived factor 1 (SDF-1) [114], S100 calcium binding protein B (S100B) [115], colony-stimulating factor-1 (CSF-1) [116] among others. </plain></SENT>
<SENT sid="191" pm="."><plain>In addition to recruitment, these factors have also been implicated in inducing tumor-promoting M2 phenotype so may prove to be important targets for glioma. </plain></SENT>
<SENT sid="192" pm="."><plain>In addition to immune suppression, M2 macrophages have been shown to produce matrix metalloproteinases (MMP), which promote glioma invasion. </plain></SENT>
<SENT sid="193" pm="."><plain>Additionally, TAM have been implicated in promoting tumor growth, angiogenesis, metastasis, and survival [117,118,119]. </plain></SENT>
</text></p><p><text><SENT sid="194" pm="."><plain>In gliomas, TAM may represent distinct lineages. </plain></SENT>
<SENT sid="195" pm="."><plain>Microglia are yolk sac derived CNS-resident macrophages, whereas macrophages are bone marrow derived cells [120]. </plain></SENT>
<SENT sid="196" pm="."><plain>Phenotypically, macrophages and microglia can be differentiated by CD45Hi and CD45Lo expression, respectively, in addition to CD11b expression [121]. </plain></SENT>
<SENT sid="197" pm="."><plain>The majority of the CD11b+ cells at the glioma site are CD45Hi, suggesting that bone marrow derived macrophages are the dominant population [121]. </plain></SENT>
<SENT sid="198" pm="."><plain>The distinct roles of these cells in tumor promotion and suppression remain currently unclear. </plain></SENT>
</text></p><p><text><SENT sid="199" pm="."><plain>Both cell types in glioma exhibit M2 phenotype polarization, such as upregulation of CD163 and CD204, as well as via secretion of M2-associated cytokine including IL-4, IL-10, and TGF-β. </plain></SENT>
<SENT sid="200" pm="."><plain>M2 macrophages are associated with tumor progression and prevent the development of anti-tumor T cell response [111,112,113,114,115,116,117,118,119,120,121,122,123]. </plain></SENT>
</text></p><p><text><SENT sid="201" pm="."><plain>Macrophage numbers correlate with increasing histological grade, suggesting these cells may be promoting tumor progression [124]. </plain></SENT>
<SENT sid="202" pm="."><plain>Depletion of CD11b+ cells in gancyclovir treated CD11b-HSVTK mice exhibited improved survival and decreased tumor size [125], further demonstrating that the majority of tumor infiltrating CD11b+ cells represents a tumor-promoting population and subsequently that depletion of this population represents a potentially viable mechanism of promoting glioma rejection. </plain></SENT>
<SENT sid="203" pm="."><plain>In addition to depletion of TAM, another strategy to improve patient survival may be to inhibit M2 and concurrently promote M1 phenotype, which promotes anti-tumor cytotoxic activity [67,111]. </plain></SENT>
<SENT sid="204" pm="."><plain>This can be achieved by various strategies, including blockade of M2-associated effector mechanisms, inducing apoptosis and/or inhibiting recruitment of M2 to the tumor site, or polarization to an M1 phenotype. </plain></SENT>
<SENT sid="205" pm="."><plain>A more comprehensive review of modulating TAM in glioma can be found in [126]. </plain></SENT>
</text></p><p><text><SENT sid="206" pm="."><plain>CSF-1 recruits peripheral macrophages to the tumor site via CSF-1 receptor (CSF-1R) and is vital to induction of M2 phenotype. </plain></SENT>
<SENT sid="207" pm="."><plain>A recent study in pre-clinical GBM models showed that a specific inhibitor of CSF-1R did not deplete TAM but instead promoted their “re-education” via inhibition of M2-associated genes, resulting in hindered glioma growth and progression [116]. </plain></SENT>
<SENT sid="208" pm="."><plain>While a decrease in an M2-like gene signature was observed, besides IL-1β, no concurrent increase in M1-associated genes was observed with CSF-1R inhibition [116]. </plain></SENT>
<SENT sid="209" pm="."><plain>While CSF-1R inhibition appears promising for treatment of glioma, it remains determined whether abrogation of M2 phenotype with no increase in M1 function of TAM is sufficient to drive tumor rejection in patients with GBM. </plain></SENT>
</text></p><p><text><SENT sid="210" pm="."><plain>Additionally, many agents that target MDSC may also alter function of TAM. </plain></SENT>
<SENT sid="211" pm="."><plain>Future investigations should complement their analysis of immune cells by examining both MDSC and TAM in order to promote the development of effective strategies targeting glioma microenvironment. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="212" pm="."><plain>2.2.6. </plain></SENT>
<SENT sid="213" pm="."><plain>Regulatory T-Cells (Tregs) </plain></SENT>
</text></title><p><text><SENT sid="214" pm="."><plain>The significance of Tregs in limiting adaptive immune response and immunotherapy is becoming increasingly clear. </plain></SENT>
<SENT sid="215" pm="."><plain>CD4+FoxP3+ Treg population correlates with impairment of T-cell proliferation in peripheral blood specimens in GBM patients [127]. </plain></SENT>
<SENT sid="216" pm="."><plain>Moreover, tumor infiltration by Tregs correlates with tumor burden, as gliomas can alter properties of T-cells, resulting in increases of Treg compartments [128]. </plain></SENT>
</text></p><p><text><SENT sid="217" pm="."><plain>Glioma stem cells (GSC) can promote immunosuppression by secretion of immunosuppressive cytokines [129]. </plain></SENT>
<SENT sid="218" pm="."><plain>They have been shown to activate STAT3 and induce a Treg phenotype, which is further compounded by hypoxic conditions [130]. </plain></SENT>
<SENT sid="219" pm="."><plain>Glioma-derived factors have also been demonstrated to induce a Treg phenotype and suppressive functions [128]. </plain></SENT>
<SENT sid="220" pm="."><plain>A recent study in a murine model demonstrated that the majority of tumor-infiltrating Tregs are thymus derived as opposed to induced Tregs [131]. </plain></SENT>
<SENT sid="221" pm="."><plain>The differential role of induced Tregs and thymically-derived Tregs in glioma development requires further elucidation. </plain></SENT>
</text></p><p><text><SENT sid="222" pm="."><plain>CD4+FoxP3+ Tregs in gliomas have been shown to express a variety of immuno-regulatory molecules, such as CD25, CTLA-4, GITR (glucocorticoid-induced TNFR family related gene), and CXCR4 at high levels [77]. </plain></SENT>
<SENT sid="223" pm="."><plain>Indoleamine 2,3 dioxygenase (IDO) expression by tumor cells has been shown to inversely correlate with survival in GBM patients [132]. </plain></SENT>
<SENT sid="224" pm="."><plain>IDO expression was also shown to correlate with Treg infiltration into the glioma site as well as GITR expression by Tregs in mouse models. </plain></SENT>
<SENT sid="225" pm="."><plain>Accumulation and activation of CD4+FoxP3+ Tregs acts as a dominant immune escape mechanism for gliomas and underline the importance of controlling tumor-infiltrating Tregs in glioma immunotherapy. </plain></SENT>
<SENT sid="226" pm="."><plain>Treg numbers may be prognostic of vaccine therapy [133]. </plain></SENT>
</text></p><p><text><SENT sid="227" pm="."><plain>Multiple studies have examined the impact of depleting Tregs in bolstering anti-glioma immunity, the majority of these studies has utilized blocking anti-CD25 (IL-2Rα) mAb. </plain></SENT>
<SENT sid="228" pm="."><plain>In murine models, systemic administration of anti-CD25 mAb decreased the number of peripheral Tregs, inhibited their suppressive function and improved T-cell effector responses [76,134,135]. </plain></SENT>
<SENT sid="229" pm="."><plain>Depletion of Tregs alone improved the survival of mice bearing gliomas [76,134]. </plain></SENT>
<SENT sid="230" pm="."><plain>However, one study demonstrated that while Treg depletion improved tumor rejection, there was a lack of persistent immunological surveillance when mice were re-challenged with tumor cells [78]. </plain></SENT>
<SENT sid="231" pm="."><plain>In this study, the combination of Treg depletion and DC vaccine established more potent immune rejection as well as persistent anti-tumor immunity, highlighting the potential need of developing combination therapies [78]. </plain></SENT>
</text></p><p><text><SENT sid="232" pm="."><plain>In human clinical trials of anti-CD25 mAb (daclizumab) and EGFRvIII peptide vaccine, administration of daclizumab depleted circulating Tregs after a single dose, which did not return to the baseline until 120 days post administration. </plain></SENT>
<SENT sid="233" pm="."><plain>There were no significant changes to effector T-cell numbers. </plain></SENT>
<SENT sid="234" pm="."><plain>However, in vitro studies exhibited increased production of IFN-γ after daclizumab treatment. </plain></SENT>
<SENT sid="235" pm="."><plain>There was a correlation between increased humoral response to EGFRvIII with decreased Treg populations. </plain></SENT>
<SENT sid="236" pm="."><plain>The authors suggest that TMZ, a lymphodepleting agent, is potentially crucial to the selective depletion of Treg by daclizumab [79]. </plain></SENT>
<SENT sid="237" pm="."><plain>Studies in rats suggests that low dose TMZ may also preferentially deplete Tregs [80], and lead to decreased CCL2 production by glioma cells and inhibition of Treg recruitment [42]. </plain></SENT>
<SENT sid="238" pm="."><plain>The compounded depletion of Tregs by chemotherapies and depleting antibodies may be a potential way to promote immunotherapy efficacy. </plain></SENT>
</text></p><p><text><SENT sid="239" pm="."><plain>Other therapies for depletion of Tregs include cyclophosphamide [136], and other IL-2R targeting antibodies, such as IL-2 targeted toxins (denileukin difilitox) [137,138] and IL-2Rα-targeted immunotoxins (LMB-2) [139]. </plain></SENT>
<SENT sid="240" pm="."><plain>However, these approaches remain to be examined in glioma models or patients as potential methods for augmenting anti-tumor responses. </plain></SENT>
<SENT sid="241" pm="."><plain>There is a recent comprehensive review of these treatments that can be found here [140]. </plain></SENT>
</text></p></sec></sec></sec><sec><title><text><SENT sid="242" pm="."><plain>3. </plain></SENT>
<SENT sid="243" pm="."><plain>Vaccine Therapy for Gliomas </plain></SENT>
</text></title><p><text><SENT sid="244" pm="."><plain>There are two major categories for cancer immunotherapy: active and passive immunotherapy. </plain></SENT>
<SENT sid="245" pm="."><plain>An active immunotherapy is a type of treatment that activates the immune system to take an active role in attacking cancer cells, such as cancer vaccines. </plain></SENT>
<SENT sid="246" pm="."><plain>On the other hand, passive immunotherapy approaches use special types of immune effector molecules or effector cells which are developed outside of a patient’s body. </plain></SENT>
<SENT sid="247" pm="."><plain>These include mAbs and adoptive cell transfer of autologous T-cells genetically engineered to attack tumor cells. </plain></SENT>
<SENT sid="248" pm="."><plain>Although passive immunotherapy approaches have recently made tremendous progresses, reviewed in [141,142], this review will focus on active immunotherapy approaches, especially clinical studies of vaccines in glioma patients. </plain></SENT>
</text></p><p><text><SENT sid="249" pm="."><plain>Recent randomized phase II–III studies in other cancer types have demonstrated therapeutic benefits of cancer vaccines [75,143], including the FDA approval for sipuleucel-T vaccine for castration-resistant prostate cancer [3], the first for non-virally induced cancers. </plain></SENT>
<SENT sid="250" pm="."><plain>These recent successes certainly spur the enthusiasm for development of effective vaccines for brain cancers, such as GBMs. </plain></SENT>
<SENT sid="251" pm="."><plain>Indeed, the history of developing brain tumor vaccines goes back to 1970s, when irradiated, autologous glioma cells were used for subcutaneous vaccinations [144]. </plain></SENT>
</text></p><p><text><SENT sid="252" pm="."><plain>Although there could be many ways to categorize the types of glioma vaccines, the current glioma vaccine approaches can be classified into two categories based on whether the vaccines are designed to target: (1) undefined, bulk glioma antigens or (2) molecularly defined antigen(s). </plain></SENT>
<SENT sid="253" pm="."><plain>There are advantages and possible disadvantages for each of the two approaches. </plain></SENT>
<SENT sid="254" pm="."><plain>The former will provide more diverse arrays of target-antigens, which may be critical to effectively treat antigenically heterogeneous tumors. </plain></SENT>
<SENT sid="255" pm="."><plain>However, those undefined antigens may be shared by normal brain cells, which may potentially lead to autoimmune encephalitis. </plain></SENT>
<SENT sid="256" pm="."><plain>While no verifiable cases of autoimmune encephalitis have been documented after active immunotherapy as of yet, there is a theoretical concern of inducing such a condition with use of checkpoint inhibitors as adjuncts to these therapies. </plain></SENT>
<SENT sid="257" pm="."><plain>On the other hand, vaccines targeting molecularly defined antigens allow more tumor-specific targeting of antigens that are uniquely or restrictedly expressed in glioma cells. </plain></SENT>
<SENT sid="258" pm="."><plain>Off-the-shelf formulation with one to several antigens may not address the heterogeneity of the individuals’ tumor antigenicity. </plain></SENT>
<SENT sid="259" pm="."><plain>Interestingly, a meta-analysis of 173 published peer-reviewed cancer vaccine trials found that patients vaccinated with whole-tumor antigen (n = 1,733) had a statistically higher rate of objective clinical responses than patients vaccinated with defined tumor antigens (n = 1,711; p &lt; 0.0001) [145]. </plain></SENT>
<SENT sid="260" pm="."><plain>In the context of glioma vaccines, Prins et al. have compared the safety, feasibility, and immune responses of two DC vaccine formats; autologous tumor-lysate (ATL)-pulsed DCs and glioma-associated antigen (GAA) peptide-pulsed DCs [146]. </plain></SENT>
<SENT sid="261" pm="."><plain>In regard to feasibility, because of HLA subtype restrictions on the GAA-DC trial, only 6 of 15 screened patients were eligible for treatment, whereas 28 of 32 patients passed eligibility screening for the ATL-DC trial. </plain></SENT>
<SENT sid="262" pm="."><plain>A significant correlation was observed between decreased Treg ratios (post-vaccination/pre-vaccination) and overall survival (p = 0.004) in patients on both trials. </plain></SENT>
<SENT sid="263" pm="."><plain>Interestingly, Treg ratios were independently prognostic for overall survival in these patients, whereas tumor pathology was not in multivariate analyses. </plain></SENT>
<SENT sid="264" pm="."><plain>These data suggest a role of Treg ratios as a possibly universal biomarker in brain tumor vaccines [146]. </plain></SENT>
</text></p><sec><title><text><SENT sid="265" pm="."><plain>3.1. </plain></SENT>
<SENT sid="266" pm="."><plain>Whole Glioma Antigen-Based Vaccines </plain></SENT>
</text></title><p><text><SENT sid="267" pm="."><plain>Initial vaccination strategies for gliomas consisted of subcutaneous inoculations of irradiated, autologous [144] or allogeneic [147] glioma cells. </plain></SENT>
<SENT sid="268" pm="."><plain>This type of vaccine has the advantage of providing a panel of multiple potential GAAs that are naturally expressed by glioma cells. </plain></SENT>
<SENT sid="269" pm="."><plain>Especially, autologous glioma cells should allow immunizations against the most relevant GAAs expressed in the patient’s tumor (i.e., tailored medicine). </plain></SENT>
<SENT sid="270" pm="."><plain>Potential downsides of this approach, however, include: (1) cumbersome procedures and quality assurance (QA)/quality control (QC) issues associated with large scale cultures of autologous glioma cells and (2) theoretical risks of autoimmune encephalomyelitis [144]. </plain></SENT>
<SENT sid="271" pm="."><plain>Nevertheless, this type of vaccine strategy has been carefully examined in GBM patients. </plain></SENT>
</text></p><p><text><SENT sid="272" pm="."><plain>Sloan et al. pioneered a combination approach of autologous GBM cell vaccine and adoptive transfer of ex vivo anti-CD3-stimualted T-cells [148]. </plain></SENT>
<SENT sid="273" pm="."><plain>The approach is currently being re-evaluated as phase I/II (NCT01081223) and phase II (NCT01290692) studies. </plain></SENT>
<SENT sid="274" pm="."><plain>Schneider et al. [149] and Steiner et al. [150] reported pilot clinical trials using autologous glioma cells modified with Newcastle-Disease-Virus, which is known to serve as an vaccine adjuvant to improve the efficacy of glioma vaccines. </plain></SENT>
<SENT sid="275" pm="."><plain>Ishikawa et al. reported a Phase I clinical trial using formalin-fixed glioma tissues as a source of antigens [151]. </plain></SENT>
<SENT sid="276" pm="."><plain>The advantage of this strategy is that formalin fixation preserves the specific antigenicity of glioma cells. </plain></SENT>
<SENT sid="277" pm="."><plain>No major adverse events were found in these studies. </plain></SENT>
</text></p><p><text><SENT sid="278" pm="."><plain>Whole glioma cell-based vaccines have often employed peripheral blood monocyte-derived DCs as the vehicle of the vaccines. </plain></SENT>
<SENT sid="279" pm="."><plain>DCs are the most potent antigen presenting cells, driving the activation of T-cells in response to invading microorganisms [152]. </plain></SENT>
<SENT sid="280" pm="."><plain>The established culture methods of DCs from human peripheral blood monocytes has generated significant interest in using DCs in novel cancer vaccination strategies [152]. </plain></SENT>
</text></p><p><text><SENT sid="281" pm="."><plain>In early DC-based vaccine studies for GBMs, DCs were pulsed with either peptides eluted from autologous glioma cells or lysate of glioma cells. </plain></SENT>
<SENT sid="282" pm="."><plain>Yu et al. reported a phase I trial of vaccinations using DCs pulsed with peptides eluted from autologous glioma cells [153]. </plain></SENT>
<SENT sid="283" pm="."><plain>Later, Liau et al. also reported a phase I trial in patients with newly diagnosed GBM using DCs pulsed with acid-eluted glioma peptides [154]. </plain></SENT>
<SENT sid="284" pm="."><plain>In this study, the authors reported the median overall survival (OS) of 23.4 months and that the benefit of the vaccine treatment was more evident in the subgroup of patients with slowly-progressing tumors and in those with tumors expressing low levels of TGF-β2. </plain></SENT>
<SENT sid="285" pm="."><plain>A phase III, randomized study is currently ongoing with this approach (NCT00045968). </plain></SENT>
</text></p><p><text><SENT sid="286" pm="."><plain>However, pulsing DCs with eluted peptides requires a large culture of autologous glioma cells and time-consuming procedures, for which QA/QC is not always feasible. </plain></SENT>
<SENT sid="287" pm="."><plain>To overcome this issue, glioma cell lysate has been used to pulse DCs in a number of trials. </plain></SENT>
<SENT sid="288" pm="."><plain>Yamanaka et al. reported a phase I/II study using DC pulsed with glioma lysate. </plain></SENT>
<SENT sid="289" pm="."><plain>Patients received either DCs matured with OK-432 or DCs without OK-432-mediated maturation [155,156]. </plain></SENT>
<SENT sid="290" pm="."><plain>GBM patients receiving mature DCs had longer survival than those receiving DCs without OK-432-mediated maturation. </plain></SENT>
<SENT sid="291" pm="."><plain>Furthermore, patients receiving both intratumoral and intradermal DC administrations demonstrated longer overall survival than those with intradermal administrations alone [156]. </plain></SENT>
<SENT sid="292" pm="."><plain>Wheeler et al. reported another phase II clinical trial with lysate-pulsed DCs [157]. </plain></SENT>
<SENT sid="293" pm="."><plain>IFN-γ production levels from post-vaccine peripheral blood mononuclear cells (PBMC) correlated significantly with patients’ OS and time to progression. </plain></SENT>
</text></p><p><text><SENT sid="294" pm="."><plain>De Vleeschouwer et al. conducted a phase II DC vaccine study in pediatric and adult patients with recurrent GBM [158]. </plain></SENT>
<SENT sid="295" pm="."><plain>DCs were loaded with autologous tumor lysate and matured with TNF-α, IL-1β as well as PGE2 and injected intradermally. </plain></SENT>
<SENT sid="296" pm="."><plain>Total resection was a predictor for better progression-free survival (PFS) both in univariable analysis and after correction for the other covariates. </plain></SENT>
<SENT sid="297" pm="."><plain>For OS, younger age and total resection were predictors of a better outcome in univariable analysis but not in multivariable analysis. </plain></SENT>
<SENT sid="298" pm="."><plain>The importance of age and a minimal residual disease status at the start of the vaccination is underscored. </plain></SENT>
<SENT sid="299" pm="."><plain>The same group subsequently conducted a phase I/II study of lysate-loaded DC vaccines in newly diagnosed patients, whose tumors were maximally resected and undergo standard-of-care chemo-radiation therapy [159]. </plain></SENT>
<SENT sid="300" pm="."><plain>These patients were administered DC vaccines weekly for 4 times after chemo-radiation therapy. </plain></SENT>
<SENT sid="301" pm="."><plain>Boost vaccines with lysates were given during the adjuvant chemotherapy with TMZ. </plain></SENT>
<SENT sid="302" pm="."><plain>PFS at six months was 75%. </plain></SENT>
<SENT sid="303" pm="."><plain>Median OS for all patients was 24 months (range: 13–44 months). </plain></SENT>
<SENT sid="304" pm="."><plain>The only serious adverse event was one case of ischemic stroke eight months postoperatively [159]. </plain></SENT>
</text></p><p><text><SENT sid="305" pm="."><plain>Prins et al. performed a phase I dose-escalation study of DC vaccines loaded with autologous tumor lysate in combination with a toll-like receptor (TLR) agonist, either imiquimod or poly:ICLC, as an immunoadjuvant in adult newly diagnosed (N = 15) or recurrent (N = 8) GBM [160]. </plain></SENT>
<SENT sid="306" pm="."><plain>T-cell infiltration was increased after vaccination in tumors resected or biopsied at recurrence; and this increase was associated with the mesenchymal gene expression signature. </plain></SENT>
<SENT sid="307" pm="."><plain>There were no grade 3 or 4 adverse events. </plain></SENT>
<SENT sid="308" pm="."><plain>Interestingly, patients with the mesenchymal gene expression signature (n = 9) had significantly better survival than a randomly selected control mesenchymal group (n = 82), whereas no difference was seen in patients with the proneural signature. </plain></SENT>
<SENT sid="309" pm="."><plain>This approach, combining lysate DC vaccines and TLR agonists, is being evaluated as a phase II study comparing relative immunological activities of imiquinod, resiquimod or poly:ICLC (NCT01204684). </plain></SENT>
<SENT sid="310" pm="."><plain>A group in University of Miami is also opening a phase I study combining DC vaccines and imiquimod application in high-grade glioma patients (NCT01808820). </plain></SENT>
</text></p><p><text><SENT sid="311" pm="."><plain>Fadul et al. focused on the immune response, PFS, and OS of newly diagnosed GBM patients treated with an intranodal autologous tumor lysate DC vaccination [161]. </plain></SENT>
<SENT sid="312" pm="."><plain>Tumor-specific CTLs correlated with both PFS and OS. </plain></SENT>
<SENT sid="313" pm="."><plain>All patients survived past 6 months post-diagnosis and a progression-free survival of 9.5 months was reported. </plain></SENT>
<SENT sid="314" pm="."><plain>Median OS was 28 months, which is significantly higher than the OS of 18–21 months in the matched historical control data. </plain></SENT>
</text></p><p><text><SENT sid="315" pm="."><plain>Although these phase II studies all demonstrate preliminary promising signs of clinical activity, each of the vaccine platforms should ultimately be evaluated in randomized phase II or III studies. </plain></SENT>
<SENT sid="316" pm="."><plain>Cho et al. conducted a phase II randomized study of autologous GBM-lysate-loaded DC vaccines [162] in newly diagnosed GBM patients who also receive standard-of-care chemo-radiation therapy. </plain></SENT>
<SENT sid="317" pm="."><plain>Eighteen patients underwent conventional treatment (surgery, radiotherapy, and chemotherapy) and received adjuvant autologous DC vaccines, and 16 patients (control group) underwent conventional treatment only. </plain></SENT>
<SENT sid="318" pm="."><plain>The median OS for the vaccine group was 31.9 months and for the control group was 15.0 months (p &lt; 0.002). </plain></SENT>
<SENT sid="319" pm="."><plain>Although the sample size is relatively small, these data strongly suggest a clinical activity of autologous GBM-lysate-loaded DC vaccines. </plain></SENT>
<SENT sid="320" pm="."><plain>Randomized phase II studies evaluating the clinical efficacy of lysate-loaded DCs are also being conducted in Austria (NCT01213407) and China (NCT01567202). </plain></SENT>
</text></p><p><text><SENT sid="321" pm="."><plain>Alternative to autologous tumor-loaded DC-based vaccines Crane et al. recently reported their results of a phase I study evaluating feasibility, safety and immunological activities of a 96 kD chaperone heat-shock protein (HSP-96) derived from surgically resected recurrent GBM. </plain></SENT>
<SENT sid="322" pm="."><plain>Of 28 patients screened, 16 patients did not receive any vaccine, including nine patients from whom inadequate amounts of tumor tissue were obtained for vaccine production. </plain></SENT>
<SENT sid="323" pm="."><plain>Nonetheless, 11 of 12 vaccine-recipients with positive peripheral blood responses against the vaccine showed a median survival of 47 weeks after surgery and vaccination, compared to 16 weeks for the single non-responder. </plain></SENT>
<SENT sid="324" pm="."><plain>Phase II multi-center studies are underway in newly diagnosed (NCT00905060) and recurrent (NCT00293423) GBM patients. </plain></SENT>
<SENT sid="325" pm="."><plain>As a novel approach targeting the whole GBM-derived antigen, DC vaccines loaded with autologous brain tumor stem cell-derived mRNA are currently being evaluated for their feasibility and safety at Duke University (NCT00890032) and Oslo University (NCT00846456) as two independent projects. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="326" pm="."><plain>3.2. </plain></SENT>
<SENT sid="327" pm="."><plain>Vaccines Targeting Glioma-Associated Antigens (GAAs) </plain></SENT>
</text></title><p><text><SENT sid="328" pm="."><plain>In contrast to the whole GBM antigen-based vaccine approaches, vaccines targeting molecularly defined GAAs are less of a concern for autoimmunity and provide “off the shelf” feasibility. </plain></SENT>
<SENT sid="329" pm="."><plain>A wide range of peptide-based vaccines have been evaluated. </plain></SENT>
<SENT sid="330" pm="."><plain>Izumoto et al. reported a Phase II clinical trial using a single Wilms’ tumor gene product (WT1)-derived peptide [163]. </plain></SENT>
<SENT sid="331" pm="."><plain>In this study, they reported a median PFS of 20 weeks and a possible association between the WT1 expression levels and clinical responses. </plain></SENT>
<SENT sid="332" pm="."><plain>An apoptosis inhibitor protein survivin has been found to be expressed in nearly 100% of gliomas, but not in normal brain tissues [164,165]. </plain></SENT>
<SENT sid="333" pm="."><plain>Ciesielski et al. have developed a novel, modified Survivin epitope SVN53-67/M57. </plain></SENT>
<SENT sid="334" pm="."><plain>This epitope elicits multi-epitope CTL and helper T-cell responses in a non-HLAA2 restricted manner against glioma cells that display wild-type survivin epitopes [166]. </plain></SENT>
<SENT sid="335" pm="."><plain>To determine the toxicity profile of the SVN53-67/M57-KLH peptide in montanide ISA 51 plus with GM-CSF, a phase I study is underway (NCT01250470). </plain></SENT>
</text></p><p><text><SENT sid="336" pm="."><plain>While GAAs are defined as antigens that are expressed in glioma cells in a relatively restricted manner, the ideal vaccine should target truly tumor-specific antigens to assure the lack of autoimmunity. </plain></SENT>
<SENT sid="337" pm="."><plain>Among the variants of EGFR, EGFRvIII is the most commonly observed in human tumors (reviewed in [167,168,169,170,171]). </plain></SENT>
<SENT sid="338" pm="."><plain>This protein results from the in-frame deletion of exons 2–7 and the generation of a novel glycine residue at the junction of exons 1 and 8. </plain></SENT>
<SENT sid="339" pm="."><plain>This novel juxtaposition of amino acids within the extra-cellular domain of the EGF receptor creates a tumor-specific and immunogenic epitope. </plain></SENT>
<SENT sid="340" pm="."><plain>EGFRvIII expression has been seen in many types of human cancers including GBM, breast adenocarcinoma, non-small cell lung carcinoma, ovarian adenocarcinoma, and prostate cancer, but is rarely observed in normal tissue, making it ideal as both a diagnostic marker and a target for immunotherapy. </plain></SENT>
<SENT sid="341" pm="."><plain>EGFRvIII is expressed in 24% to 67% of GBM cases, and in patients surviving &gt; or =1 year, the expression of EGFRvIII is an independent negative prognostic indicator [172,173]. </plain></SENT>
<SENT sid="342" pm="."><plain>Sampson et al. recently reported a Phase II study targeting the EGFRvIII epitope in newly diagnosed GBM patients who received gross total resection [174]. </plain></SENT>
<SENT sid="343" pm="."><plain>This study reported a median PFS of 14.2 months and a median OS of 26.0 months. </plain></SENT>
<SENT sid="344" pm="."><plain>In addition, they identified that the development of specific antibody or delayed-type hypersensitivity responses to EGFRvIII significantly correlated with the OS. </plain></SENT>
<SENT sid="345" pm="."><plain>Interestingly, recurrent GBMs following the vaccines did not express EGFRvIII, indicating the outgrowth of antigen-loss variants of the GBM cells. </plain></SENT>
<SENT sid="346" pm="."><plain>Randomized studies are underway to determine the activity of this approach in newly diagnosed (NCT01480479) and recurrent (NCT01498328) GBMs as phase III and II studies, respectively. </plain></SENT>
<SENT sid="347" pm="."><plain>Also, as an extension of this regimen, a new approach combining the EGFRvIII-targeted vaccine and anti-CD25 mAbs, which are designed to deplete regulatory T-cells, is being evaluated in a phase I study (NCT00626015). </plain></SENT>
</text></p><p><text><SENT sid="348" pm="."><plain>When single or oligo antigens are selected and targeted by vaccines, it also seems necessary to diversify the response to wider arrays of GAAs, and harness the concepts of epitope spreading to address the problems of tumor immune escape, while avoiding the augmentation of deleterious CNS autoimmune responses [175]. </plain></SENT>
<SENT sid="349" pm="."><plain>An ideal GBM vaccine therefore should be targeting multiple GAAs that can be recognized by individual patients’ immune system as immunogenic antigens. </plain></SENT>
</text></p><p><text><SENT sid="350" pm="."><plain>Yajima et al. reported a phase I study of peptide-based vaccinations in patients with recurrent malignant gliomas [176]. </plain></SENT>
<SENT sid="351" pm="."><plain>In this study, prior to the first vaccine, each patient’s PBMCs were evaluated in vitro for cellular and humoral responses against a panel of antigens, and peptides that induced a positive response were used for vaccinations. </plain></SENT>
<SENT sid="352" pm="."><plain>The regimen was well tolerated and resulted in an 89-week median survival of treated patients. </plain></SENT>
<SENT sid="353" pm="."><plain>However, there is little evidence that the antigens used in this study are expressed in gliomas at high levels. </plain></SENT>
<SENT sid="354" pm="."><plain>More recently, as an extension of the approach, Terasaki et al. reported a phase I trial using 14 HLA-A24-binding peptides [177]. </plain></SENT>
<SENT sid="355" pm="."><plain>This study evaluated immune responses with dose escalation of peptides and defined 3 mg/peptide as the phase II-recommended dose. </plain></SENT>
</text></p><p><text><SENT sid="356" pm="."><plain>Phuphanich et al. performed a phase I study evaluating the safety and immune responses to an autologous DC vaccine pulsed with class I peptides from GAAs expressed on gliomas and overexpressed in their cancer stem cell population [178]. </plain></SENT>
<SENT sid="357" pm="."><plain>The authors targeted HLA-A1- or A2-binding epitopes derived from HER2, TRP-2, gp100, MAGE-1, IL13Rα2, and AIM-2. </plain></SENT>
<SENT sid="358" pm="."><plain>They observed correlations of increased PFS and OS with quantitative expression of melanoma-associated antigen (MAGE)1 and absent in melanoma (AIM)-2. </plain></SENT>
<SENT sid="359" pm="."><plain>Interestingly, five patients who underwent a second resection for recurrent tumors showed decrease or absence in expression levels of a GBM stem cell marker, CD133. </plain></SENT>
<SENT sid="360" pm="."><plain>Median PFS in newly diagnosed patients was 16.9 months, and median OS was 38.4 months. </plain></SENT>
<SENT sid="361" pm="."><plain>A phase II, randomized, double-blind, controlled-phase IIb study with this approach is underway (NCT01280552). </plain></SENT>
</text></p><p><text><SENT sid="362" pm="."><plain>In our laboratory, based on our preclinical data demonstrating that type-1 CTLs are capable of mediating effective anti-CNS tumor immunity [179,180,181,182], we have completed a phase I/II study of vaccines evaluating safety and immunological activities of vaccines using α-type-1-polarized DCs (αDC1) that are able to produce high levels of IL-12 and induce long-lived type-1 T-cell responses [183]. </plain></SENT>
<SENT sid="363" pm="."><plain>In this study, patients with recurrent malignant glioma received intra-lymphnodal injection of αDC1 loaded with synthetic peptides for GAA epitopes and administration of poly:ICLC in HLA-A2+ patients with recurrent malignant gliomas. </plain></SENT>
<SENT sid="364" pm="."><plain>GAAs for these peptides are EphA2, IL-13Rα2, YKL-40, and gp100. </plain></SENT>
<SENT sid="365" pm="."><plain>The regimen was well-tolerated and induced positive immune responses against at least one of the vaccination-targeted GAAs in peripheral blood mononuclear cells in 83% of patients. </plain></SENT>
<SENT sid="366" pm="."><plain>Peripheral blood samples demonstrated significant upregulation of type 1 cytokines and chemokines, including interferon-α and CXCL10. </plain></SENT>
<SENT sid="367" pm="."><plain>For at least 12 months, nine patients achieved progression-free status. </plain></SENT>
<SENT sid="368" pm="."><plain>Two patients (one with recurrent GBM and one with recurrent anaplastic astrocytoma) demonstrated a sustained complete response. </plain></SENT>
<SENT sid="369" pm="."><plain>IL-12 production levels by αDC1 positively correlated with time to progression. </plain></SENT>
<SENT sid="370" pm="."><plain>These data support safety, immunogenicity, and preliminary clinical activity of poly:ICLC-boosted αDC1-based vaccines and warrant further development of this approach. </plain></SENT>
<SENT sid="371" pm="."><plain>With regard to the use of IL-13Rα2HLA-derived class I epitopes, Iwami et al. have demonstrated positive T-cell responses against an HLA-A24-binding IL-13Rα2-derived epitope in their phase I vaccine study in patients with malignant glioma [184]. </plain></SENT>
</text></p><p><text><SENT sid="372" pm="."><plain>Recently, Dutoit et al. have identified an attractive class of HLA-A2-binding epitopes that are naturally presented in HLA-A2 molecules of GBM tissues [185]. </plain></SENT>
<SENT sid="373" pm="."><plain>They eluted &gt;3,000 HLA-A2-restricted peptides from fresh GBM tumor tissues. </plain></SENT>
<SENT sid="374" pm="."><plain>They prioritized further investigation of 10 GBM-associated antigens based on high expression in tumors, very low or absent expression in healthy tissues, implication in gliomagenesis and immunogenicity. </plain></SENT>
<SENT sid="375" pm="."><plain>Patients with GBM showed no T cell tolerance to these peptides, and patients’ CD8+ T cells stimulated with these peptides demonstrated specific lysis of GBM cells. </plain></SENT>
<SENT sid="376" pm="."><plain>Furthermore, antigen-specific CD8+ T cells were present in GBM tissues. </plain></SENT>
<SENT sid="377" pm="."><plain>The peptides identified in this study are currently being evaluated as phase I studies in newly diagnosed GBM patients through Cancer Research UK (ClinicalTrials.gov Identifier: NCT01222221) and the National Cancer Institute (NCT01403285). </plain></SENT>
</text></p><p><text><SENT sid="378" pm="."><plain>In addition to these vaccine strategies administered peripherally, several types of viral therapies, most of which are administered directly to the intracranial tumor site, can also be considered immunotherapy, as they are expected to cause an immune response as a part of the therapeutic mechanisms (e.g., NCT01814813 and NCT00751270). </plain></SENT>
</text></p></sec></sec><sec><title><text><SENT sid="379" pm="."><plain>4. </plain></SENT>
<SENT sid="380" pm="."><plain>Applications of Immunotherapy for Pediatric Brain Tumors </plain></SENT>
</text></title><p><text><SENT sid="381" pm="."><plain>In comparison to the extensive research that has been conducted on immunotherapy for adult brain tumors, the number of pediatric immunotherapy studies is relatively modest. </plain></SENT>
<SENT sid="382" pm="."><plain>However, significant recent interest has been focused on the use of vaccination or immunomodulation in high-risk tumors, such as brainstem gliomas and high-grade non-brainstem gliomas, as well as recurrent tumors, such as low-grade gliomas and ependymomas. </plain></SENT>
<SENT sid="383" pm="."><plain>Such approaches are particularly promising in the pediatric age group since affected patients are likely to have intact immunity. </plain></SENT>
<SENT sid="384" pm="."><plain>Recent pilot studies of immunotherapy for pediatric malignant brain tumors have suggested that children may exhibit a productive immunological response as well as clinical activity [158,186,187,188,189], although these small pilot studies were primarily designed to assess safety, and conclusions of the clinical efficacy are inferential, at best. </plain></SENT>
</text></p><p><text><SENT sid="385" pm="."><plain>Most studies to date, including several that are ongoing (e.g., NCT01326104), have involved administration of tumor lysate or tumor RNA with DC [158,186,187]. </plain></SENT>
<SENT sid="386" pm="."><plain>As noted earlier, these approaches have the advantage of exposing the immune system to a host of tumor-related antigens, but the disadvantage is that ex vivo manipulation is required and that substantial amounts of tumor are required as the vaccine source, which may be a limiting factor for children with deep-seated tumors, such as diffuse brainstem gliomas where biopsies, if performed, are generally quite small. </plain></SENT>
<SENT sid="387" pm="."><plain>An alternative approach, using an allogeneic tumor cell lysate, has also been proposed (NCT01400672) for lesions, such as brainstem gliomas, that do not have readily accessible tumor material. </plain></SENT>
</text></p><p><text><SENT sid="388" pm="."><plain>As an additional strategy, a handful of recent studies have focused on peptide-based vaccination approaches, including NCT01058850, which administers an EGFRvIII peptide; and NCT00935545, which administers a multipeptide cocktail, both of which are in progress. </plain></SENT>
</text></p><p><text><SENT sid="389" pm="."><plain>An ongoing study at our institution combines subcutaneous vaccinations with peptides for GAA epitopes emulsified in Montanide-ISA-51 given every 3 weeks for eight courses along with intramuscular injections of an immunoadjuvant, poly-ICLC, in HLA-A2+ children with newly diagnosed brainstem gliomas (BSG), high-grade gliomas (HGG), or recurrent gliomas [188,189]. </plain></SENT>
<SENT sid="390" pm="."><plain>The GAAs targeted in this trial are EphA2, IL13Rα2, and survivin. </plain></SENT>
<SENT sid="391" pm="."><plain>Among 33 patients enrolled through June 30, 2012 (to allow a minimal follow-up duration of at least one year for toxicity monitoring or until disease progression or off-study criteria were met); 14 had previously untreated BSG and received irradiation alone, six had newly diagnosed BSG treated with irradiation and concurrent chemotherapy, four had recurrent high-grade glioma, four had newly diagnosed high-grade glioma treated with irradiation and concurrent chemotherapy, and five had multiple recurrent low-grade glioma, after failure of numerous prior regimens. </plain></SENT>
<SENT sid="392" pm="."><plain>The primary objectives of this study were to assess safety, given that at the time it was launched, it this was the first such “peptide + adjuvant” vaccine trial for pediatric brain tumors. </plain></SENT>
</text></p><p><text><SENT sid="393" pm="."><plain>Principal toxicities have included local injection site reactions and low grade fevers and flu-like symptoms in almost all patients, which have been generally mild, as well as several instances of possible immunologically-mediated pseudoprogression. </plain></SENT>
<SENT sid="394" pm="."><plain>Both clinical and immunological responses have been observed, although formal outcome analysis is pending, since patients remain on study. </plain></SENT>
<SENT sid="395" pm="."><plain>A multi-institutional trial of this GAA cocktail in conjunction with the immunoadjuvants Imiquimod [160,190] and GM-CSF is planned within the Pediatric Brain Tumor Consortium. </plain></SENT>
</text></p><p><text><SENT sid="396" pm="."><plain>In addition to the above approaches, recent interest has been directed at the implementation of approaches targeting immune checkpoint inhibitors, such as ipilumimab and anti-PD1. </plain></SENT>
<SENT sid="397" pm="."><plain>The advancement of such studies is awaiting preliminary safety data in adult patients with brain tumors. </plain></SENT>
</text></p></sec><SecTag type="CONCL"><sec><title><text><SENT sid="398" pm="."><plain>5. </plain></SENT>
<SENT sid="399" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><text><SENT sid="400" pm="."><plain>We reviewed recent progresses in the field of brain tumor immunology with particular foci in the area of immune-checkpoint mechanisms and development of active immunotherapy strategies. </plain></SENT>
<SENT sid="401" pm="."><plain>In the last decade, a number of novel immunoregulatory mechanisms have been identified and characterized, and most of them seem to mediate immunosuppression in GBM patients. </plain></SENT>
<SENT sid="402" pm="."><plain>Promising news is that specific mAbs designed to block each of those “checkpoints” have been developed and show efficacy in other cancers, such as melanoma. </plain></SENT>
<SENT sid="403" pm="."><plain>The main reason we focused our review in these areas is because we believe that development of active immunotherapy approaches should integrate those checkpoint-blockade agents to enhance the efficacy of therapeutic approaches. </plain></SENT>
<SENT sid="404" pm="."><plain>With these agents available, it is going to be quite an exciting time in the field. </plain></SENT>
<SENT sid="405" pm="."><plain>Nonetheless, there are inherent challenges in combinatory approaches. </plain></SENT>
<SENT sid="406" pm="."><plain>For example, when each of these agents is owned by separate industries with intellectual property, creative combinatorial strategies may not be implemented as efficiently as one would expect. </plain></SENT>
<SENT sid="407" pm="."><plain>In addition, we need to address whether the mode of delivery (i.e., local vs. systemic) significantly impacts the safety and efficacy of antibody- and compound-based approaches if the target is within the brain. </plain></SENT>
<SENT sid="408" pm="."><plain>The eventual success of immunotherapies for brain tumors will be dependent upon not only an in-depth understanding of immunology behind the brain and brain tumors, but also collaboration and teamwork for the development of novel trials that address multiple layers of immunological challenges in gliomas. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><title>Acknowledgments</title><p><text4fund><text><SENT sid="409" pm="."><plain>Financial support: The National Institutes of Health [R01NS055140, P01CA132714 (HO) and T32 CA082084 (BA)] and Musella Foundation for Brain Tumor Research and Information (HO). </plain></SENT>
</text></text4fund></p></ack></SecTag><notes><title>Conflicts of Interest</title><p>Hideho Okada is an inventor in the U.S. Patent Application No. 60,611, 797 (Utility Patent Application) “Identification of An IL-13 Receptor Alpha2 Peptide Analogue Capable of Enhancing Stimulation of Glioma-Specific CTL Response”. An exclusive licensing agreement has been completed on this application between University of Pittsburgh and Stemline, Inc. Due to the potential conflicts of interest, Hideho Okada did not solely interpret any data in the current manuscript.</p></notes><SecTag type="REF"><ref-list><title>References</title><ref id="B1-cancers-05-01379"><text><SENT sid="410" pm="."><plain>1.HodiF.S.O’DayS.J.McDermottD.F.WeberR.W.SosmanJ.A.HaanenJ.B.GonzalezR.RobertC.SchadendorfD.HasselJ.C. Improved survival with Ipilimumab in patients with metastatic melanoma N. </plain></SENT>
<SENT sid="411" pm="."><plain>Engl. </plain></SENT>
<SENT sid="412" pm="."><plain>J. </plain></SENT>
<SENT sid="413" pm="."><plain>Med. 2010 363 711 723 10.1056/NEJMoa1003466 20525992 </plain></SENT>
</text></ref><ref id="B2-cancers-05-01379"><text><SENT sid="414" pm="."><plain>2. MorganR.A.ChinnasamyN.Abate-DagaD.GrosA.RobbinsP.F.ZhengZ.DudleyM.E.FeldmanS.A.YangJ.C.SherryR.M. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy J. </plain></SENT>
<SENT sid="415" pm="."><plain>Immunother. 2013 36 133 151 23377668 </plain></SENT>
</text></ref><ref id="B3-cancers-05-01379"><text><SENT sid="416" pm="."><plain>3. KantoffP.W.HiganoC.S.ShoreN.D.BergerE.R.SmallE.J.PensonD.F.RedfernC.H.FerrariA.C.DreicerR.SimsR.B. Sipuleucel-T immunotherapy for Castration-resistant prostate cancer N. </plain></SENT>
<SENT sid="417" pm="."><plain>Engl. </plain></SENT>
<SENT sid="418" pm="."><plain>J. </plain></SENT>
<SENT sid="419" pm="."><plain>Med. 2010 363 411 422 10.1056/NEJMoa1001294 20818862 </plain></SENT>
</text></ref><ref id="B4-cancers-05-01379"><text><SENT sid="420" pm="."><plain>4. OkadaH.KohanbashG.ZhuX.KastenhuberE.R.HojiA.UedaR.FujitaM. Immunotherapeutic approaches for glioma Crit. </plain></SENT>
<SENT sid="421" pm="."><plain>Rev. </plain></SENT>
<SENT sid="422" pm="."><plain>Immunol. 2009 29 1 42 10.1615/CritRevImmunol.v29.i1.10 19348609 </plain></SENT>
</text></ref><ref id="B5-cancers-05-01379"><text><SENT sid="423" pm="."><plain>5. WalkerP.R.CalzasciaT.de TriboletN.DietrichP.Y. T-cell immune responses in the brain and their relevance for cerebral malignancies Brain Res. </plain></SENT>
<SENT sid="424" pm="."><plain>Rev. 2003 42 97 122 10.1016/S0165-0173(03)00141-3 12738053 </plain></SENT>
</text></ref><ref id="B6-cancers-05-01379"><text><SENT sid="425" pm="."><plain>6. GorelikL.FlavellR.A. Transforming growth factor-beta in T-cell biology Nat. </plain></SENT>
<SENT sid="426" pm="."><plain>Rev. </plain></SENT>
<SENT sid="427" pm="."><plain>Immunol. 2002 2 46 53 10.1038/nri704 11905837 </plain></SENT>
</text></ref><ref id="B7-cancers-05-01379"><text><SENT sid="428" pm="."><plain>7. GomezG.G.KruseC.A. Cellular and functional characterization of immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes reveals their up-regulated synthesis of biologically active TGF-beta J. </plain></SENT>
<SENT sid="429" pm="."><plain>Immunother. 2007 30 261 273 10.1097/01.cji.0000211339.81211.25 17414317 </plain></SENT>
</text></ref><ref id="B8-cancers-05-01379"><text><SENT sid="430" pm="."><plain>8. UedaR.FujitaM.ZhuX.SasakiK.KastenhuberE.R.KohanbashG.McDonaldH.A.HarperJ.LonningS.OkadaH. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines Clin. </plain></SENT>
<SENT sid="431" pm="."><plain>Cancer Res. 2009 15 6551 6559 10.1158/1078-0432.CCR-09-1067 19861464 </plain></SENT>
</text></ref><ref id="B9-cancers-05-01379"><text><SENT sid="432" pm="."><plain>9. EiseleG.WischhusenJ.MittelbronnM.MeyermannR.WaldhauerI.SteinleA.WellerM.FrieseM.A. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells Brain 2006 129 2416 2425 10.1093/brain/awl205 16891318 </plain></SENT>
</text></ref><ref id="B10-cancers-05-01379"><text><SENT sid="433" pm="."><plain>10. CraneC.A.HanS.J.BarryJ.J.AhnB.J.LanierL.L.ParsaA.T. TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients Neuro-oncology 2010 12 7 13 10.1093/neuonc/nop009 20150362 </plain></SENT>
</text></ref><ref id="B11-cancers-05-01379"><text><SENT sid="434" pm="."><plain>11. FrieseM.A.WischhusenJ.WickW.WeilerM.EiseleG.SteinleA.WellerM. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo Cancer Res. 2004 64 7596 7603 15492287 </plain></SENT>
</text></ref><ref id="B12-cancers-05-01379"><text><SENT sid="435" pm="."><plain>12. NaumannU.MaassP.GleskeA.K.AulwurmS.WellerM.EiseleG. Glioma gene therapy with soluble transforming growth factor-beta receptors II and III Int. </plain></SENT>
<SENT sid="436" pm="."><plain>J. </plain></SENT>
<SENT sid="437" pm="."><plain>Oncol. 2008 33 759 765 18813789 </plain></SENT>
</text></ref><ref id="B13-cancers-05-01379"><text><SENT sid="438" pm="."><plain>13. WithamT.F.VillaL.YangT.PollackI.F.OkadaH.RobbinsP.D.ChambersW.H. Expression of a soluble transforming growth factor-beta (TGFbeta) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo J. </plain></SENT>
<SENT sid="439" pm="."><plain>Neurooncol. 2003 64 63 69 12952287 </plain></SENT>
</text></ref><ref id="B14-cancers-05-01379"><text><SENT sid="440" pm="."><plain>14. LiuY.WangQ.Kleinschmidt-DeMastersB.K.FranzusoffA.NgK.Y.LilleheiK.O. TGF-beta2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors J. </plain></SENT>
<SENT sid="441" pm="."><plain>Neurooncol. 2007 81 149 162 16941073 </plain></SENT>
</text></ref><ref id="B15-cancers-05-01379"><text><SENT sid="442" pm="."><plain>15. AnidoJ.Saez-BorderiasA.Gonzalez-JuncaA.RodonL.FolchG.CarmonaM.A.Prieto-SanchezR.M.BarbaI.Martinez-SaezE.PrudkinL. TGF-beta receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma Cancer Cell 2010 18 655 668 21156287 </plain></SENT>
</text></ref><ref id="B16-cancers-05-01379"><text><SENT sid="443" pm="."><plain>16. YeX.Z.XuS.L.XinY.H.YuS.C.PingY.F.ChenL.XiaoH.L.WangB.YiL.WangQ.L. Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-beta1 signaling pathway J. </plain></SENT>
<SENT sid="444" pm="."><plain>Immunol. 2012 189 444 453 22664874 </plain></SENT>
</text></ref><ref id="B17-cancers-05-01379"><text><SENT sid="445" pm="."><plain>17. HardeeM.E.MarciscanoA.E.Medina-RamirezC.M.ZagzagD.NarayanaA.LonningS.M.Barcellos-HoffM.H. Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-beta Cancer Res. 2012 72 4119 4129 22693253 </plain></SENT>
</text></ref><ref id="B18-cancers-05-01379"><text><SENT sid="446" pm="."><plain>18. PenuelasS.AnidoJ.Prieto-SanchezR.M.FolchG.BarbaI.CuartasI.Garcia-DoradoD.PocaM.A.SahuquilloJ.BaselgaJ. TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma Cancer Cell 2009 15 315 327 19345330 </plain></SENT>
</text></ref><ref id="B19-cancers-05-01379"><text><SENT sid="447" pm="."><plain>19. IkushimaH.TodoT.InoY.TakahashiM.MiyazawaK.MiyazonoK. Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors Cell Stem Cell 2009 5 504 514 19896441 </plain></SENT>
</text></ref><ref id="B20-cancers-05-01379"><text><SENT sid="448" pm="."><plain>20. SongL.LiuL.WuZ.LiY.YingZ.LinC.WuJ.HuB.ChengS.Y.LiM. TGF-beta induces miR-182 to sustain NF-kappaB activation in glioma subsets J. </plain></SENT>
<SENT sid="449" pm="."><plain>Clin. </plain></SENT>
<SENT sid="450" pm="."><plain>Invest. 2012 122 3563 3578 10.1172/JCI62339 23006329 </plain></SENT>
</text></ref><ref id="B21-cancers-05-01379"><text><SENT sid="451" pm="."><plain>21. JosephJ.V.BalasubramaniyanV.WalenkampA.KruytF.A. TGF-beta as a therapeutic target in high grade gliomas—Promises and challenges Biochem. </plain></SENT>
<SENT sid="452" pm="."><plain>Pharmacol. 2013 85 478 485 10.1016/j.bcp.2012.11.005 23159669 </plain></SENT>
</text></ref><ref id="B22-cancers-05-01379"><text><SENT sid="453" pm="."><plain>22. MooreK.W.de Waal MalefytR.CoffmanR.L.O’GarraA. Interleukin-10 and the interleukin-10 receptor Annu. </plain></SENT>
<SENT sid="454" pm="."><plain>Rev. </plain></SENT>
<SENT sid="455" pm="."><plain>Immunol. 2001 19 683 765 10.1146/annurev.immunol.19.1.683 11244051 </plain></SENT>
</text></ref><ref id="B23-cancers-05-01379"><text><SENT sid="456" pm="."><plain>23. SaidE.A.DupuyF.P.TrautmannL.ZhangY.ShiY.El-FarM.HillB.J.NotoA.AncutaP.PeretzY. Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection Nat. </plain></SENT>
<SENT sid="457" pm="."><plain>Med. 2010 16 452 459 10.1038/nm.2106 20208540 </plain></SENT>
</text></ref><ref id="B24-cancers-05-01379"><text><SENT sid="458" pm="."><plain>24. NittaT.HishiiM.SatoK.OkumuraK. Selective expression of interleukin-10 gene within glioblastoma multiforme Brain Res. 1994 649 122 128 10.1016/0006-8993(94)91055-3 7953624 </plain></SENT>
</text></ref><ref id="B25-cancers-05-01379"><text><SENT sid="459" pm="."><plain>25. HuettnerC.CzubS.KerkauS.RoggendorfW.TonnJ.C. Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro Anticancer Res. 1997 17 3217 3224 9413151 </plain></SENT>
</text></ref><ref id="B26-cancers-05-01379"><text><SENT sid="460" pm="."><plain>26. OshimaM.DinchukJ.E.KargmanS.L.OshimaH.HancockB.KwongE.TrzaskosJ.M.EvansJ.F.TaketoM.M. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2) Cell 1996 87 803 809 10.1016/S0092-8674(00)81988-1 8945508 </plain></SENT>
</text></ref><ref id="B27-cancers-05-01379"><text><SENT sid="461" pm="."><plain>27. OnguruO.GamsizkanM.UlutinC.GunhanO. Cyclooxygenase-2 (Cox-2) expression and angiogenesis in glioblastoma Neuropathology 2008 28 29 34 10.1111/j.1440-1789.2007.00828.x 18181832 </plain></SENT>
</text></ref><ref id="B28-cancers-05-01379"><text><SENT sid="462" pm="."><plain>28. SharmaS.YangS.C.ZhuL.ReckampK.GardnerB.BaratelliF.HuangM.BatraR.K.DubinettS.M. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer Cancer Res. 2005 65 5211 5220 10.1158/0008-5472.CAN-05-0141 15958566 </plain></SENT>
</text></ref><ref id="B29-cancers-05-01379"><text><SENT sid="463" pm="."><plain>29. KalinskiP.VieiraP.L.SchuitemakerJ.H.de JongE.C.KapsenbergM.L. Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer Blood 2001 97 3466 3469 10.1182/blood.V97.11.3466 11369638 </plain></SENT>
</text></ref><ref id="B30-cancers-05-01379"><text><SENT sid="464" pm="."><plain>30. KalinskiP.HilkensC.M.SnijdersA.SnijdewintF.G.KapsenbergM.L. IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells J. </plain></SENT>
<SENT sid="465" pm="."><plain>Immunol. 1997 159 28 35 9200435 </plain></SENT>
</text></ref><ref id="B31-cancers-05-01379"><text><SENT sid="466" pm="."><plain>31. KurodaE.SugiuraT.OkadaK.ZekiK.YamashitaU. Prostaglandin E2 up-regulates macrophage-derived chemokine production but suppresses IFN-inducible protein-10 production by APC J. </plain></SENT>
<SENT sid="467" pm="."><plain>Immunol. 2001 166 1650 1658 11160207 </plain></SENT>
</text></ref><ref id="B32-cancers-05-01379"><text><SENT sid="468" pm="."><plain>32. LebreM.C.BurwellT.VieiraP.L.LoraJ.CoyleA.J.KapsenbergM.L.ClausenB.E.de JongE.C. Differential expression of inflammatory chemokines by Th1- and Th2-cell promoting dendritic cells: A role for different mature dendritic cell populations in attracting appropriate effector cells to peripheral sites of inflammation Immunol. </plain></SENT>
<SENT sid="469" pm="."><plain>Cell Biol. 2005 83 525 535 10.1111/j.1440-1711.2005.01365.x 16174103 </plain></SENT>
</text></ref><ref id="B33-cancers-05-01379"><text><SENT sid="470" pm="."><plain>33. McIlroyA.CaronG.BlanchardS.FremauxI.DulucD.DelnesteY.ChevaillerA.JeanninP. Histamine and prostaglandin E up-regulate the production of Th2-attracting chemokines (CCL17 and CCL22) and down-regulate IFN-gamma-induced CXCL10 production by immature human dendritic cells Immunology 2006 117 507 516 10.1111/j.1365-2567.2006.02326.x 16556265 </plain></SENT>
</text></ref><ref id="B34-cancers-05-01379"><text><SENT sid="471" pm="."><plain>34. SinhaP.ClementsV.K.FultonA.M.Ostrand-RosenbergS. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells Cancer Res. 2007 67 4507 4513 10.1158/0008-5472.CAN-06-4174 17483367 </plain></SENT>
</text></ref><ref id="B35-cancers-05-01379"><text><SENT sid="472" pm="."><plain>35. OchoaA.C.ZeaA.H.HernandezC.RodriguezP.C. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma Clin. </plain></SENT>
<SENT sid="473" pm="."><plain>Cancer Res. 2007 13 721s 726s 10.1158/1078-0432.CCR-06-2197 17255300 </plain></SENT>
</text></ref><ref id="B36-cancers-05-01379"><text><SENT sid="474" pm="."><plain>36. RodriguezP.C.OchoaA.C. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: Mechanisms and therapeutic perspectives Immunol. </plain></SENT>
<SENT sid="475" pm="."><plain>Rev. 2008 222 180 191 10.1111/j.1600-065X.2008.00608.x 18364002 </plain></SENT>
</text></ref><ref id="B37-cancers-05-01379"><text><SENT sid="476" pm="."><plain>37. FujitaM.KohanbashG.Fellows-MayleW.HamiltonR.L.KomoharaY.DeckerS.A.OhlfestJ.R.OkadaH. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells Cancer Res. 2011 71 2664 2674 10.1158/0008-5472.CAN-10-3055 21324923 </plain></SENT>
</text></ref><ref id="B38-cancers-05-01379"><text><SENT sid="477" pm="."><plain>38. DesbailletsI.TadaM.deT.N.DiserensA.C.HamouM.F.van MeirE.G. Human astrocytomas and glioblastomas express monocyte chemoattractant protein-1 (MCP-1) in vivo and in vitro Int. </plain></SENT>
<SENT sid="478" pm="."><plain>J. </plain></SENT>
<SENT sid="479" pm="."><plain>Cancer 1994 58 240 247 10.1002/ijc.2910580216 7517920 </plain></SENT>
</text></ref><ref id="B39-cancers-05-01379"><text><SENT sid="480" pm="."><plain>39. TakeshimaH.KuratsuJ.TakeyaM.YoshimuraT.UshioY. Expression and localization of messenger RNA and protein for monocyte chemoattractant protein-1 in human malignant glioma J. </plain></SENT>
<SENT sid="481" pm="."><plain>Neurosurg. 1994 80 1056 1062 10.3171/jns.1994.80.6.1056 8189261 </plain></SENT>
</text></ref><ref id="B40-cancers-05-01379"><text><SENT sid="482" pm="."><plain>40. SalcedoR.PonceM.L.YoungH.A.WassermanK.WardJ.M.KleinmanH.K.OppenheimJ.J.MurphyW.J. Human endothelial cells express CCR2 and respond to MCP-1: Direct role of MCP-1 in angiogenesis and tumor progression Blood 2000 96 34 40 10891427 </plain></SENT>
</text></ref><ref id="B41-cancers-05-01379"><text><SENT sid="483" pm="."><plain>41. HuangB.LeiZ.ZhaoJ.GongW.LiuJ.ChenZ.LiuY.LiD.YuanY.ZhangG.M.FengZ.H. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers Cancer Lett. 2007 252 86 92 10.1016/j.canlet.2006.12.012 17257744 </plain></SENT>
</text></ref><ref id="B42-cancers-05-01379"><text><SENT sid="484" pm="."><plain>42. JordanJ.T.SunW.HussainS.F.DeanguloG.PrabhuS.S.HeimbergerA.B. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy Cancer Immunol. </plain></SENT>
<SENT sid="485" pm="."><plain>Immunother. 2008 57 123 131 10.1007/s00262-007-0336-x 17522861 </plain></SENT>
</text></ref><ref id="B43-cancers-05-01379"><text><SENT sid="486" pm="."><plain>43. FujitaM.ScheurerM.E.DeckerS.A.McDonaldH.A.KohanbashG.KastenhuberE.R.KatoH.BondyM.L.OhlfestJ.R.OkadaH. Role of type 1 IFNs in antiglioma immunosurveillance―Using mouse studies to guide examination of novel prognostic markers in humans Clin. </plain></SENT>
<SENT sid="487" pm="."><plain>Cancer Res. 2010 16 3409 3419 10.1158/1078-0432.CCR-10-0644 20472682 </plain></SENT>
</text></ref><ref id="B44-cancers-05-01379"><text><SENT sid="488" pm="."><plain>44. ZhuX.FujitaM.SnyderL.A.OkadaH. Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy J. </plain></SENT>
<SENT sid="489" pm="."><plain>Neurooncol. 2011 104 83 92 10.1007/s11060-010-0473-5 21116835 </plain></SENT>
</text></ref><ref id="B45-cancers-05-01379"><text><SENT sid="490" pm="."><plain>45. KagiD.VignauxF.LedermannB.BurkiK.DepraetereV.NagataS.HengartnerH.GolsteinP. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity Science 1994 265 528 530 7518614 </plain></SENT>
</text></ref><ref id="B46-cancers-05-01379"><text><SENT sid="491" pm="."><plain>46. SaasP.WalkerP.R.HahneM.QuiquerezA.L.SchnurigerV.PerrinG.FrenchL.van MeirE.G.de TriboletN.TschoppJ. Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain? J. </plain></SENT>
<SENT sid="492" pm="."><plain>Clin. </plain></SENT>
<SENT sid="493" pm="."><plain>Invest. 1997 99 1173 1178 10.1172/JCI119273 9077524 </plain></SENT>
</text></ref><ref id="B47-cancers-05-01379"><text><SENT sid="494" pm="."><plain>47. WalkerP.R.SaasP.DietrichP.Y. Role of Fas ligand (CD95L) in immune escape: The tumor cell strikes back J. </plain></SENT>
<SENT sid="495" pm="."><plain>Immunol. 1997 158 4521 4524 9144461 </plain></SENT>
</text></ref><ref id="B48-cancers-05-01379"><text><SENT sid="496" pm="."><plain>48. ShinoharaH.YagitaH.IkawaY.OyaizuN. Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase activation Cancer Res. 2000 60 1766 1772 10749152 </plain></SENT>
</text></ref><ref id="B49-cancers-05-01379"><text><SENT sid="497" pm="."><plain>49. PoulakiV.MitsiadesC.S.MitsiadesN. The role of Fas and FasL as mediators of anticancer chemotherapy Drug Resist. </plain></SENT>
<SENT sid="498" pm="."><plain>Updat. 2001 4 233 242 10.1054/drup.2001.0210 11991678 </plain></SENT>
</text></ref><ref id="B50-cancers-05-01379"><text><SENT sid="499" pm="."><plain>50. XiaS.RosenE.M.LaterraJ. Sensitization of glioma cells to Fas-dependent apoptosis by chemotherapy-induced oxidative stress Cancer Res. 2005 65 5248 5255 10.1158/0008-5472.CAN-04-4332 15958570 </plain></SENT>
</text></ref><ref id="B51-cancers-05-01379"><text><SENT sid="500" pm="."><plain>51. GiraudS.BessetteB.BodaC.LalloueF.PetitD.MathonnetM.JauberteauM.O. In vitro apoptotic induction of human glioblastoma cells by Fas ligand plus etoposide and in vivo antitumour activity of combined drugs in xenografted nude rats Int. </plain></SENT>
<SENT sid="501" pm="."><plain>J. </plain></SENT>
<SENT sid="502" pm="."><plain>Oncol. 2007 30 273 281 17143538 </plain></SENT>
</text></ref><ref id="B52-cancers-05-01379"><text><SENT sid="503" pm="."><plain>52. JansenT.TylerB.MankowskiJ.L.RecinosV.R.PradillaG.LegnaniF.LaterraJ.OliviA. FasL gene knock-down therapy enhances the antiglioma immune response Neuro-oncology 2010 12 482 489 20406899 </plain></SENT>
</text></ref><ref id="B53-cancers-05-01379"><text><SENT sid="504" pm="."><plain>53. HoI.A.NgW.H.LamP.Y. FasL and FADD delivery by a glioma-specific and cell cycle-dependent HSV-1 amplicon virus enhanced apoptosis in primary human brain tumors Mol. </plain></SENT>
<SENT sid="505" pm="."><plain>Cancer 2010 9 e270 10.1186/1476-4598-9-270  </plain></SENT>
</text></ref><ref id="B54-cancers-05-01379"><text><SENT sid="506" pm="."><plain>54. McCoyK.D.Le GrosG. The role of CTLA-4 in the regulation of T cell immune responses Immunol. </plain></SENT>
<SENT sid="507" pm="."><plain>Cell Biol. 1999 77 1 10 10101680 </plain></SENT>
</text></ref><ref id="B55-cancers-05-01379"><text><SENT sid="508" pm="."><plain>55. FriedlineR.H.BrownD.S.NguyenH.KornfeldH.LeeJ.ZhangY.ApplebyM.DerS.D.KangJ.ChambersC.A. CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance J. </plain></SENT>
<SENT sid="509" pm="."><plain>Exp. </plain></SENT>
<SENT sid="510" pm="."><plain>Med. 2009 206 421 434 10.1084/jem.20081811 19188497 </plain></SENT>
</text></ref><ref id="B56-cancers-05-01379"><text><SENT sid="511" pm="."><plain>56. FecciP.E.OchiaiH.MitchellD.A.GrossiP.M.SweeneyA.E.ArcherG.E.CummingsT.AllisonJ.P.BignerD.D.SampsonJ.H. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function Clin. </plain></SENT>
<SENT sid="512" pm="."><plain>Cancer Res. 2007 13 2158 2167 10.1158/1078-0432.CCR-06-2070 17404100 </plain></SENT>
</text></ref><ref id="B57-cancers-05-01379"><text><SENT sid="513" pm="."><plain>57. AgarwallaP.BarnardZ.FecciP.DranoffG.CurryW.T.Jr. Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors J. </plain></SENT>
<SENT sid="514" pm="."><plain>Immunother. 2012 35 385 389 10.1097/CJI.0b013e3182562d59 22576343 </plain></SENT>
</text></ref><ref id="B58-cancers-05-01379"><text><SENT sid="515" pm="."><plain>58. ChenL. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity Nat. </plain></SENT>
<SENT sid="516" pm="."><plain>Rev. </plain></SENT>
<SENT sid="517" pm="."><plain>Immunol. 2004 4 336 347 10.1038/nri1349 15122199 </plain></SENT>
</text></ref><ref id="B59-cancers-05-01379"><text><SENT sid="518" pm="."><plain>59. WintterleS.SchreinerB.MitsdoerfferM.SchneiderD.ChenL.MeyermannR.WellerM.WiendlH. Expression of the B7-related molecule B7-H1 by glioma cells: A potential mechanism of immune paralysis Cancer Res. 2003 63 7462 7467 14612546 </plain></SENT>
</text></ref><ref id="B60-cancers-05-01379"><text><SENT sid="519" pm="."><plain>60. ParsaA.T.WaldronJ.S.PannerA.CraneC.A.ParneyI.F.BarryJ.J.CacholaK.E.MurrayJ.C.TihanT.JensenM.C. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma Nat. </plain></SENT>
<SENT sid="520" pm="."><plain>Med. 2007 13 84 88 10.1038/nm1517 17159987 </plain></SENT>
</text></ref><ref id="B61-cancers-05-01379"><text><SENT sid="521" pm="."><plain>61. HanS.J.AhnB.J.WaldronJ.S.YangI.FangS.CraneC.A.PieperR.O.ParsaA.T. Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: A paradoxical mechanism of immune evasion Neuro. </plain></SENT>
<SENT sid="522" pm="."><plain>Rep. 2009 20 1597 1602  </plain></SENT>
</text></ref><ref id="B62-cancers-05-01379"><text><SENT sid="523" pm="."><plain>62. CraneC.PannerA.PieperR.O.ArbiserJ.ParsaA.T. Honokiol-mediated inhibition of PI3K/mTOR pathway: A potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function J. </plain></SENT>
<SENT sid="524" pm="."><plain>Immunother. 2009 32 585 592 10.1097/CJI.0b013e3181a8efe6 19483651 </plain></SENT>
</text></ref><ref id="B63-cancers-05-01379"><text><SENT sid="525" pm="."><plain>63. ZengJ.SeeA.P.PhallenJ.JacksonC.M.BelcaidZ.RuzevickJ.DurhamN.MeyerC.HarrisT.J.AlbesianoE. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas Int. </plain></SENT>
<SENT sid="526" pm="."><plain>J. </plain></SENT>
<SENT sid="527" pm="."><plain>Radiat. </plain></SENT>
<SENT sid="528" pm="."><plain>Oncol. </plain></SENT>
<SENT sid="529" pm="."><plain>Biol. </plain></SENT>
<SENT sid="530" pm="."><plain>Phys. 2013 86 343 349 10.1016/j.ijrobp.2012.12.025 23462419 </plain></SENT>
</text></ref><ref id="B64-cancers-05-01379"><text><SENT sid="531" pm="."><plain>64. TopalianS.L.HodiF.S.BrahmerJ.R.GettingerS.N.SmithD.C.McDermottD.F.PowderlyJ.D.CarvajalR.D.SosmanJ.A.AtkinsM.B. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N. </plain></SENT>
<SENT sid="532" pm="."><plain>Engl. </plain></SENT>
<SENT sid="533" pm="."><plain>J. </plain></SENT>
<SENT sid="534" pm="."><plain>Med. 2012 366 2443 2454 10.1056/NEJMoa1200690 22658127 </plain></SENT>
</text></ref><ref id="B65-cancers-05-01379"><text><SENT sid="535" pm="."><plain>65. BrahmerJ.R.TykodiS.S.ChowL.Q.HwuW.J.TopalianS.L.HwuP.DrakeC.G.CamachoL.H.KauhJ.OdunsiK. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N. </plain></SENT>
<SENT sid="536" pm="."><plain>Engl. </plain></SENT>
<SENT sid="537" pm="."><plain>J. </plain></SENT>
<SENT sid="538" pm="."><plain>Med. 2012 366 2455 2465 10.1056/NEJMoa1200694 22658128 </plain></SENT>
</text></ref><ref id="B66-cancers-05-01379"><text><SENT sid="539" pm="."><plain>66. GabrilovichD.I.Ostrand-RosenbergS.BronteV. Coordinated regulation of myeloid cells by tumours Nat. </plain></SENT>
<SENT sid="540" pm="."><plain>Rev. </plain></SENT>
<SENT sid="541" pm="."><plain>Immunol. 2012 12 253 268 10.1038/nri3175 22437938 </plain></SENT>
</text></ref><ref id="B67-cancers-05-01379"><text><SENT sid="542" pm="."><plain>67. SicaA.SchioppaT.MantovaniA.AllavenaP. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy Eur. </plain></SENT>
<SENT sid="543" pm="."><plain>J. </plain></SENT>
<SENT sid="544" pm="."><plain>Cancer 2006 42 717 727 10.1016/j.ejca.2006.01.003 16520032 </plain></SENT>
</text></ref><ref id="B68-cancers-05-01379"><text><SENT sid="545" pm="."><plain>68. OhkuraN.KitagawaY.SakaguchiS. Development and maintenance of regulatory T cells Immunity 2013 38 414 423 10.1016/j.immuni.2013.03.002 23521883 </plain></SENT>
</text></ref><ref id="B69-cancers-05-01379"><text><SENT sid="546" pm="."><plain>69. CondamineT.GabrilovichD.I. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function Trends Immunol. 2011 32 19 25 10.1016/j.it.2010.10.002 21067974 </plain></SENT>
</text></ref><ref id="B70-cancers-05-01379"><text><SENT sid="547" pm="."><plain>70. GabrilovichD.I.NagarajS. Myeloid-derived suppressor cells as regulators of the immune system Nat. </plain></SENT>
<SENT sid="548" pm="."><plain>Rev. </plain></SENT>
<SENT sid="549" pm="."><plain>Immunol. 2009 9 162 174 10.1038/nri2506 19197294 </plain></SENT>
</text></ref><ref id="B71-cancers-05-01379"><text><SENT sid="550" pm="."><plain>71. LiuC.Y.WangY.M.WangC.L.FengP.H.KoH.W.LiuY.H.WuY.C.ChuY.ChungF.T.KuoC.H. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14-/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer J. </plain></SENT>
<SENT sid="551" pm="."><plain>Cancer Res. </plain></SENT>
<SENT sid="552" pm="."><plain>Clin. </plain></SENT>
<SENT sid="553" pm="."><plain>Oncol. 2010 136 35 45 10.1007/s00432-009-0634-0 19572148 </plain></SENT>
</text></ref><ref id="B72-cancers-05-01379"><text><SENT sid="554" pm="."><plain>72. SchmielauJ.FinnO.J. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients Cancer Res. 2001 61 4756 4760 11406548 </plain></SENT>
</text></ref><ref id="B73-cancers-05-01379"><text><SENT sid="555" pm="."><plain>73. SrivastavaM.K.SinhaP.ClementsV.K.RodriguezP.Ostrand-RosenbergS. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine Cancer Res. 2010 70 68 77 10.1158/0008-5472.CAN-09-2587 20028852 </plain></SENT>
</text></ref><ref id="B74-cancers-05-01379"><text><SENT sid="556" pm="."><plain>74. YounJ.I.GabrilovichD.I. The biology of myeloid-derived suppressor cells: The blessing and the curse of morphological and functional heterogeneity Eur. </plain></SENT>
<SENT sid="557" pm="."><plain>J. </plain></SENT>
<SENT sid="558" pm="."><plain>Immunol. 2010 40 2969 2975 10.1002/eji.201040895 21061430 </plain></SENT>
</text></ref><ref id="B75-cancers-05-01379"><text><SENT sid="559" pm="."><plain>75. WalterS.WeinschenkT.StenzlA.ZdrojowyR.PluzanskaA.SzczylikC.StaehlerM.BruggerW.DietrichP.-Y.MendrzykR. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival Nat. </plain></SENT>
<SENT sid="560" pm="."><plain>Med. 2012 18 1254 1261 10.1038/nm.2883 22842478 </plain></SENT>
</text></ref><ref id="B76-cancers-05-01379"><text><SENT sid="561" pm="."><plain>76. FecciP.E.SweeneyA.E.GrossiP.M.NairS.K.LearnC.A.MitchellD.A.CuiX.CummingsT.J.BignerD.D.GilboaE. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells Clin. </plain></SENT>
<SENT sid="562" pm="."><plain>Cancer Res. 2006 12 4294 4305 10.1158/1078-0432.CCR-06-0053 16857805 </plain></SENT>
</text></ref><ref id="B77-cancers-05-01379"><text><SENT sid="563" pm="."><plain>77. GrauerO.M.NierkensS.BenninkE.ToonenL.W.BoonL.WesselingP.SutmullerR.P.AdemaG.J. CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo Int. </plain></SENT>
<SENT sid="564" pm="."><plain>J. </plain></SENT>
<SENT sid="565" pm="."><plain>Cancer 2007 121 95 105 10.1002/ijc.22607 17315190 </plain></SENT>
</text></ref><ref id="B78-cancers-05-01379"><text><SENT sid="566" pm="."><plain>78. MaesW.RosasG.G.VerbinnenB.BoonL.de VleeschouwerS.CeuppensJ.L.van GoolS.W. DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma Neuro-oncology 2009 11 529 542 10.1215/15228517-2009-004 19336528 </plain></SENT>
</text></ref><ref id="B79-cancers-05-01379"><text><SENT sid="567" pm="."><plain>79. SampsonJ.H.SchmittlingR.J.ArcherG.E.CongdonK.L.NairS.K.ReapE.A.DesjardinsA.FriedmanA.H.FriedmanH.S.HerndonJ.E.2nd A pilot study of IL-2Ralpha blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma PLoS One 2012 7 e31046 10.1371/journal.pone.0031046 22383993 </plain></SENT>
</text></ref><ref id="B80-cancers-05-01379"><text><SENT sid="568" pm="."><plain>80. BanissiC.GhiringhelliF.ChenL.CarpentierA.F. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model Cancer Immunol. </plain></SENT>
<SENT sid="569" pm="."><plain>Immunother. 2009 58 1627 1634 10.1007/s00262-009-0671-1 19221744 </plain></SENT>
</text></ref><ref id="B81-cancers-05-01379"><text><SENT sid="570" pm="."><plain>81. CzabankaM.BruennerJ.ParmaksizG.BrogginiT.TopalovicM.BayerlS.H.AufG.KremenetskaiaI.NieminenM.JabouilleA. Combined temozolomide and sunitinib treatment leads to better tumour control but increased vascular resistance in O-methylguanine methyltransferase-methylated gliomas Eur. </plain></SENT>
<SENT sid="571" pm="."><plain>J. </plain></SENT>
<SENT sid="572" pm="."><plain>Cancer 2013 49 2243 2252 10.1016/j.ejca.2013.02.019  </plain></SENT>
</text></ref><ref id="B82-cancers-05-01379"><text><SENT sid="573" pm="."><plain>82. D’AmicoR.LeiL.KennedyB.C.SistiJ.EbianaV.CrismanC.ChristensenJ.G.GilO.RosenfeldS.S.CanollP. The addition of Sunitinib to radiation delays tumor growth in a murine model of glioblastoma Neurol. </plain></SENT>
<SENT sid="574" pm="."><plain>Res. 2012 34 252 261 22449730 </plain></SENT>
</text></ref><ref id="B83-cancers-05-01379"><text><SENT sid="575" pm="."><plain>83. JoshiA.D.LoilomeW.SiuI.M.TylerB.GalliaG.L.RigginsG.J. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy PLoS One 2012 7 e44372 23056179 </plain></SENT>
</text></ref><ref id="B84-cancers-05-01379"><text><SENT sid="576" pm="."><plain>84. NeynsB.SadonesJ.ChaskisC.DujardinM.EveraertH.LvS.DuerinckJ.TynninenO.NupponenN.MichotteA. Phase II study of sunitinib malate in patients with recurrent high-grade glioma J. </plain></SENT>
<SENT sid="577" pm="."><plain>Neurooncol. 2011 103 491 501 10.1007/s11060-010-0402-7 20872043 </plain></SENT>
</text></ref><ref id="B85-cancers-05-01379"><text><SENT sid="578" pm="."><plain>85. PanE.YuD.YueB.PotthastL.ChowdharyS.SmithP.ChamberlainM. A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma J. </plain></SENT>
<SENT sid="579" pm="."><plain>Neurooncol. 2012 110 111 118 10.1007/s11060-012-0943-z 22832897 </plain></SENT>
</text></ref><ref id="B86-cancers-05-01379"><text><SENT sid="580" pm="."><plain>86. KreislT.N.SmithP.SulJ.SalgadoC.IwamotoF.M.ShihJ.H.FineH.A. Continuous daily sunitinib for recurrent glioblastoma J. </plain></SENT>
<SENT sid="581" pm="."><plain>Neurooncol. 2013 111 41 48 10.1007/s11060-012-0988-z 23086433 </plain></SENT>
</text></ref><ref id="B87-cancers-05-01379"><text><SENT sid="582" pm="."><plain>87. NiuC.S.LiM.W.NiY.F.ChenJ.M.MeiJ.M.LiJ.FuX.M. Effect of all-trans retinoic acid on the proliferation and differentiation of brain tumor stem cells J. </plain></SENT>
<SENT sid="583" pm="."><plain>Exp. </plain></SENT>
<SENT sid="584" pm="."><plain>Clin. </plain></SENT>
<SENT sid="585" pm="."><plain>Cancer Res. 2010 29 e113 10.1186/1756-9966-29-113  </plain></SENT>
</text></ref><ref id="B88-cancers-05-01379"><text><SENT sid="586" pm="."><plain>88. KarsyM.AlbertL.TobiasM.E.MuraliR.Jhanwar-UniyalM. All-trans retinoic acid modulates cancer stem cells of glioblastoma multiforme in an MAPK-dependent manner Anticancer Res. 2010 30 4915 4920 21187470 </plain></SENT>
</text></ref><ref id="B89-cancers-05-01379"><text><SENT sid="587" pm="."><plain>89. BlackK.L.YinD.OngJ.M.HuJ.KondaB.M.WangX.KoM.K.BayanJ.A.SacapanoM.R.EspinozaA. PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model Brain Res. 2008 1230 290 302 10.1016/j.brainres.2008.06.122 18674521 </plain></SENT>
</text></ref><ref id="B90-cancers-05-01379"><text><SENT sid="588" pm="."><plain>90. RaychaudhuriB.RaymanP.IrelandJ.KoJ.RiniB.BordenE.C.GarciaJ.VogelbaumM.A.FinkeJ. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma Neuro-oncology 2011 13 591 599 10.1093/neuonc/nor042 21636707 </plain></SENT>
</text></ref><ref id="B91-cancers-05-01379"><text><SENT sid="589" pm="."><plain>91. NajjarY.G.FinkeJ.H. Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer Front. </plain></SENT>
<SENT sid="590" pm="."><plain>Oncol. 2013 3 e49  </plain></SENT>
</text></ref><ref id="B92-cancers-05-01379"><text><SENT sid="591" pm="."><plain>92. NefedovaY.FishmanM.ShermanS.WangX.BegA.A.GabrilovichD.I. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells Cancer Res. 2007 67 11021 11028 10.1158/0008-5472.CAN-07-2593 18006848 </plain></SENT>
</text></ref><ref id="B93-cancers-05-01379"><text><SENT sid="592" pm="."><plain>93. IclozanC.AntoniaS.ChiapporiA.ChenD.T.GabrilovichD. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer Cancer Immunol. </plain></SENT>
<SENT sid="593" pm="."><plain>Immunother. 2013 62 909 918 10.1007/s00262-013-1396-8 23589106 </plain></SENT>
</text></ref><ref id="B94-cancers-05-01379"><text><SENT sid="594" pm="."><plain>94. MirzaN.FishmanM.FrickeI.DunnM.NeugerA.M.FrostT.J.LushR.M.AntoniaS.GabrilovichD.I. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients Cancer Res. 2006 66 9299 9307 10.1158/0008-5472.CAN-06-1690 16982775 </plain></SENT>
</text></ref><ref id="B95-cancers-05-01379"><text><SENT sid="595" pm="."><plain>95. LathersD.M.ClarkJ.I.AchilleN.J.YoungM.R. Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3 Cancer Immunol. </plain></SENT>
<SENT sid="596" pm="."><plain>Immunother. 2004 53 422 430 10.1007/s00262-003-0459-7 14648070 </plain></SENT>
</text></ref><ref id="B96-cancers-05-01379"><text><SENT sid="597" pm="."><plain>96. HartmannJ.T.KanzL. Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition Arch. </plain></SENT>
<SENT sid="598" pm="."><plain>Dermatol. 2008 144 1525 1526 10.1001/archderm.144.11.1525 19015436 </plain></SENT>
</text></ref><ref id="B97-cancers-05-01379"><text><SENT sid="599" pm="."><plain>97. WoodL. Sunitinib malate for the treatment of renal cell carcinoma Expert Opin. </plain></SENT>
<SENT sid="600" pm="."><plain>Pharmacother. 2012 13 1323 1336 10.1517/14656566.2012.689130 22607009 </plain></SENT>
</text></ref><ref id="B98-cancers-05-01379"><text><SENT sid="601" pm="."><plain>98. Van CruijsenH.van der VeldtA.A.VrolingL.OosterhoffD.BroxtermanH.J.ScheperR.J.GiacconeG.HaanenJ.B.van den EertweghA.J.BovenE. Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival Clin. </plain></SENT>
<SENT sid="602" pm="."><plain>Cancer Res. 2008 14 5884 5892 10.1158/1078-0432.CCR-08-0656 18794101 </plain></SENT>
</text></ref><ref id="B99-cancers-05-01379"><text><SENT sid="603" pm="."><plain>99. FinkeJ.H.RiniB.IrelandJ.RaymanP.RichmondA.GolshayanA.WoodL.ElsonP.GarciaJ.DreicerR. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients Clin. </plain></SENT>
<SENT sid="604" pm="."><plain>Cancer Res. 2008 14 6674 6682 18927310 </plain></SENT>
</text></ref><ref id="B100-cancers-05-01379"><text><SENT sid="605" pm="."><plain>100. Ozao-ChoyJ.MaG.KaoJ.WangG.X.MeseckM.SungM.SchwartzM.DivinoC.M.PanP.Y.ChenS.H. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies Cancer Res. 2009 69 2514 2522 10.1158/0008-5472.CAN-08-4709 19276342 </plain></SENT>
</text></ref><ref id="B101-cancers-05-01379"><text><SENT sid="606" pm="."><plain>101. KoJ.S.RaymanP.IrelandJ.SwaidaniS.LiG.BuntingK.D.RiniB.FinkeJ.H.CohenP.A. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained Cancer Res. 2010 70 3526 3536 20406969 </plain></SENT>
</text></ref><ref id="B102-cancers-05-01379"><text><SENT sid="607" pm="."><plain>102. BoseA.TaylorJ.L.AlberS.WatkinsS.C.GarciaJ.A.RiniB.I.KoJ.S.CohenP.A.FinkeJ.H.StorkusW.J. Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination Int. </plain></SENT>
<SENT sid="608" pm="."><plain>J. </plain></SENT>
<SENT sid="609" pm="."><plain>Cancer 2011 129 2158 2170 21170961 </plain></SENT>
</text></ref><ref id="B103-cancers-05-01379"><text><SENT sid="610" pm="."><plain>103. KujawskiM.ZhangC.HerrmannA.ReckampK.ScutoA.JensenM.DengJ.FormanS.FiglinR.YuH. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects Cancer Res. 2010 70 9599 9610 10.1158/0008-5472.CAN-10-1293 21118964 </plain></SENT>
</text></ref><ref id="B104-cancers-05-01379"><text><SENT sid="611" pm="."><plain>104. SuzukiE.KapoorV.JassarA.S.KaiserL.R.AlbeldaS.M. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity Clin. </plain></SENT>
<SENT sid="612" pm="."><plain>Cancer Res. 2005 11 6713 6721 10.1158/1078-0432.CCR-05-0883 16166452 </plain></SENT>
</text></ref><ref id="B105-cancers-05-01379"><text><SENT sid="613" pm="."><plain>105. VincentJ.MignotG.ChalminF.LadoireS.BruchardM.ChevriauxA.MartinF.ApetohL.RebeC.GhiringhelliF. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity Cancer Res. 2010 70 3052 3061 10.1158/0008-5472.CAN-09-3690 20388795 </plain></SENT>
</text></ref><ref id="B106-cancers-05-01379"><text><SENT sid="614" pm="."><plain>106. RodriguezP.C.HernandezC.P.QuicenoD.DubinettS.M.ZabaletaJ.OchoaJ.B.GilbertJ.OchoaA.C. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma J. </plain></SENT>
<SENT sid="615" pm="."><plain>Exp. </plain></SENT>
<SENT sid="616" pm="."><plain>Med. 2005 202 931 939 10.1084/jem.20050715 16186186 </plain></SENT>
</text></ref><ref id="B107-cancers-05-01379"><text><SENT sid="617" pm="."><plain>107. ObermajerN.MuthuswamyR.OdunsiK.EdwardsR.P.KalinskiP. PGE2-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment Cancer Res. 2011 71 7463 7470 22025564 </plain></SENT>
</text></ref><ref id="B108-cancers-05-01379"><text><SENT sid="618" pm="."><plain>108. SerafiniP.MeckelK.KelsoM.NoonanK.CalifanoJ.KochW.DolcettiL.BronteV.BorrelloI. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function J. </plain></SENT>
<SENT sid="619" pm="."><plain>Exp. </plain></SENT>
<SENT sid="620" pm="."><plain>Med. 2006 203 2691 2702 10.1084/jem.20061104 17101732 </plain></SENT>
</text></ref><ref id="B109-cancers-05-01379"><text><SENT sid="621" pm="."><plain>109. UmanskyV.SevkoA. Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation Cancer Immunol. </plain></SENT>
<SENT sid="622" pm="."><plain>Immunother. 2012 61 275 282 10.1007/s00262-011-1164-6 22120757 </plain></SENT>
</text></ref><ref id="B110-cancers-05-01379"><text><SENT sid="623" pm="."><plain>110. GiomettoB.BozzaF.FaresinF.AlessioL.MingrinoS.TavolatoB. Immune infiltrates and cytokines in gliomas Acta Neurochir. 1996 138 50 56 8686525 </plain></SENT>
</text></ref><ref id="B111-cancers-05-01379"><text><SENT sid="624" pm="."><plain>111. KomoharaY.OhnishiK.KuratsuJ.TakeyaM. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas J. </plain></SENT>
<SENT sid="625" pm="."><plain>Pathol. 2008 216 15 24 10.1002/path.2370 18553315 </plain></SENT>
</text></ref><ref id="B112-cancers-05-01379"><text><SENT sid="626" pm="."><plain>112. AltermanR.L.StanleyE.R. Colony stimulating factor-1 expression in human glioma Mol. </plain></SENT>
<SENT sid="627" pm="."><plain>Chem. </plain></SENT>
<SENT sid="628" pm="."><plain>Neuropathol. 1994 21 177 188 10.1007/BF02815350 8086034 </plain></SENT>
</text></ref><ref id="B113-cancers-05-01379"><text><SENT sid="629" pm="."><plain>113. ConiglioS.J.EugeninE.DobrenisK.StanleyE.R.WestB.L.SymonsM.H.SegallJ.E. Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling Mol. </plain></SENT>
<SENT sid="630" pm="."><plain>Med. 2012 18 519 527 22294205 </plain></SENT>
</text></ref><ref id="B114-cancers-05-01379"><text><SENT sid="631" pm="."><plain>114. WangS.C.HongJ.H.HsuehC.ChiangC.S. Tumor-secreted SDF-1 promotes glioma invasiveness and TAM tropism toward hypoxia in a murine astrocytoma model Lab. </plain></SENT>
<SENT sid="632" pm="."><plain>Invest. 2012 92 151 162 10.1038/labinvest.2011.128 21894147 </plain></SENT>
</text></ref><ref id="B115-cancers-05-01379"><text><SENT sid="633" pm="."><plain>115. WangH.ZhangL.ZhangI.Y.ChenX.da FonsecaA.WuS.RenH.BadieS.SadeghiS.OuyangM. S100B promotes glioma growth through chemoattraction of myeloid-derived macrophages Clin. </plain></SENT>
<SENT sid="634" pm="."><plain>Cancer Res. 2013 19 3764 3775 10.1158/1078-0432.CCR-12-3725 23719262 </plain></SENT>
</text></ref><ref id="B116-cancers-05-01379"><text><SENT sid="635" pm="."><plain>116. PyonteckS.M.AkkariL.SchuhmacherA.J.BowmanR.L.SevenichL.QuailD.F.OlsonO.C.QuickM.L.HuseJ.T.TeijeiroV. CSF-1R inhibition alters macrophage polarization and blocks glioma progression Nat. </plain></SENT>
<SENT sid="636" pm="."><plain>Med. 2013 19 1264 1272 10.1038/nm.3337 24056773 </plain></SENT>
</text></ref><ref id="B117-cancers-05-01379"><text><SENT sid="637" pm="."><plain>117. BettingerI.ThanosS.PaulusW. Microglia promote glioma migration Acta Neuropathol. 2002 103 351 355 10.1007/s00401-001-0472-x 11904754 </plain></SENT>
</text></ref><ref id="B118-cancers-05-01379"><text><SENT sid="638" pm="."><plain>118. MarkovicD.S.GlassR.SynowitzM.RooijenN.KettenmannH. Microglia stimulate the invasiveness of glioma cells by increasing the activity of metalloprotease-2 J. </plain></SENT>
<SENT sid="639" pm="."><plain>Neuropathol. </plain></SENT>
<SENT sid="640" pm="."><plain>Exp. </plain></SENT>
<SENT sid="641" pm="."><plain>Neurol. 2005 64 754 762 10.1097/01.jnen.0000178445.33972.a9 16141784 </plain></SENT>
</text></ref><ref id="B119-cancers-05-01379"><text><SENT sid="642" pm="."><plain>119. RaoJ.S. Molecular mechanisms of glioma invasiveness: The role of proteases Nat. </plain></SENT>
<SENT sid="643" pm="."><plain>Rev. </plain></SENT>
<SENT sid="644" pm="."><plain>Cancer 2003 3 489 501 10.1038/nrc1121 12835669 </plain></SENT>
</text></ref><ref id="B120-cancers-05-01379"><text><SENT sid="645" pm="."><plain>120. GinhouxF.GreterM.LeboeufM.NandiS.SeeP.GokhanS.MehlerM.F.ConwayS.J.NgL.G.StanleyE.R. Fate mapping analysis reveals that adult microglia derive from primitive macrophages Science 2010 330 841 845 10.1126/science.1194637 20966214 </plain></SENT>
</text></ref><ref id="B121-cancers-05-01379"><text><SENT sid="646" pm="."><plain>121. FordA.L.GoodsallA.L.HickeyW.F.SedgwickJ.D. Normal adult ramified microglia separated from other central nervous system macrophages by flow cytometric sorting. </plain></SENT>
<SENT sid="647" pm="."><plain>Phenotypic differences defined and direct ex vivo antigen presentation to myelin basic protein-reactive CD4+ T cells compared J. </plain></SENT>
<SENT sid="648" pm="."><plain>Immunol. 1995 154 4309 4321 7722289 </plain></SENT>
</text></ref><ref id="B122-cancers-05-01379"><text><SENT sid="649" pm="."><plain>122. ZouJ.P.MorfordL.A.ChougnetC.DixA.R.BrooksA.G.TorresN.ShumanJ.D.ColiganJ.E.BrooksW.H.RoszmanT.L. Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers J. </plain></SENT>
<SENT sid="650" pm="."><plain>Immunol. 1999 162 4882 4892 10202033 </plain></SENT>
</text></ref><ref id="B123-cancers-05-01379"><text><SENT sid="651" pm="."><plain>123. OkadaM.SaioM.KitoY.OheN.YanoH.YoshimuraS.IwamaT.TakamiT. Tumor-associated macrophage/microglia infiltration in human gliomas is correlated with MCP-3, but not MCP-1 Int. </plain></SENT>
<SENT sid="652" pm="."><plain>J. </plain></SENT>
<SENT sid="653" pm="."><plain>Oncol. 2009 34 1621 1627 19424580 </plain></SENT>
</text></ref><ref id="B124-cancers-05-01379"><text><SENT sid="654" pm="."><plain>124. NishieA.OnoM.ShonoT.FukushiJ.OtsuboM.OnoueH.ItoY.InamuraT.IkezakiK.FukuiM. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas Clin. </plain></SENT>
<SENT sid="655" pm="."><plain>Cancer Res. 1999 5 1107 1113 10353745 </plain></SENT>
</text></ref><ref id="B125-cancers-05-01379"><text><SENT sid="656" pm="."><plain>125. ZhaiH.HeppnerF.L.TsirkaS.E. Microglia/macrophages promote glioma progression Glia 2011 59 472 485 10.1002/glia.21117 21264953 </plain></SENT>
</text></ref><ref id="B126-cancers-05-01379"><text><SENT sid="657" pm="."><plain>126. WeiJ.GabrusiewiczK.HeimbergerA. The controversial role of microglia in malignant gliomas Clin. </plain></SENT>
<SENT sid="658" pm="."><plain>Dev. </plain></SENT>
<SENT sid="659" pm="."><plain>Immunol. 2013 2013 e285246  </plain></SENT>
</text></ref><ref id="B127-cancers-05-01379"><text><SENT sid="660" pm="."><plain>127. FecciP.E.MitchellD.A.WhitesidesJ.F.XieW.FriedmanA.H.ArcherG.E.HerndonJ.E.BignerD.D.DranoffG.SampsonJ.H. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma Cancer Res. 2006 66 3294 3302 10.1158/0008-5472.CAN-05-3773 16540683 </plain></SENT>
</text></ref><ref id="B128-cancers-05-01379"><text><SENT sid="661" pm="."><plain>128. CraneC.A.AhnB.J.HanS.J.ParsaA.T.  Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: Implications for immunotherapy Neuro-oncology 2012 14 584 595 10.1093/neuonc/nos014 22406925 </plain></SENT>
</text></ref><ref id="B129-cancers-05-01379"><text><SENT sid="662" pm="."><plain>129. WeiJ.BarrJ.KongL.Y.WangY.WuA.SharmaA.K.GuminJ.HenryV.ColmanH.PriebeW. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway Mol. </plain></SENT>
<SENT sid="663" pm="."><plain>Cancer Ther. 2010 9 67 78 20053772 </plain></SENT>
</text></ref><ref id="B130-cancers-05-01379"><text><SENT sid="664" pm="."><plain>130. WeiJ.WuA.KongL.Y.WangY.FullerG.FoktI.MelilloG.PriebeW.HeimbergerA.B. Hypoxia potentiates glioma-mediated immunosuppression PLoS One 2011 6 e16195 10.1371/journal.pone.0016195 21283755 </plain></SENT>
</text></ref><ref id="B131-cancers-05-01379"><text><SENT sid="665" pm="."><plain>131. WainwrightD.A.SenguptaS.HanY.LesniakM.S. Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors Neuro-oncology 2011 13 1308 1323 10.1093/neuonc/nor134 21908444 </plain></SENT>
</text></ref><ref id="B132-cancers-05-01379"><text><SENT sid="666" pm="."><plain>132. WainwrightD.A.BalyasnikovaI.V.ChangA.L.AhmedA.U.MoonK.S.AuffingerB.TobiasA.L.HanY.LesniakM.S. IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival Clin. </plain></SENT>
<SENT sid="667" pm="."><plain>Cancer Res. 2012 18 6110 6121 10.1158/1078-0432.CCR-12-2130 22932670 </plain></SENT>
</text></ref><ref id="B133-cancers-05-01379"><text><SENT sid="668" pm="."><plain>133. FongB.JinR.WangX.SafaeeM.LisieroD.N.YangI.LiG.LiauL.M.PrinsR.M. Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients PLoS One 2012 7 e32614 22485134 </plain></SENT>
</text></ref><ref id="B134-cancers-05-01379"><text><SENT sid="669" pm="."><plain>134. GrauerO.M.SutmullerR.P.van MarenW.JacobsJ.F.BenninkE.ToonenL.W.NierkensS.AdemaG.J. Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model Int. </plain></SENT>
<SENT sid="670" pm="."><plain>J. </plain></SENT>
<SENT sid="671" pm="."><plain>Cancer 2008 122 1794 1802 18076066 </plain></SENT>
</text></ref><ref id="B135-cancers-05-01379"><text><SENT sid="672" pm="."><plain>135. MaesW.VerschuereT.van HoylandtA.BoonL.van GoolS. Depletion of regulatory T cells in a mouse experimental glioma model through anti-CD25 treatment results in the infiltration of non-immunosuppressive myeloid cells in the brain Clin. </plain></SENT>
<SENT sid="673" pm="."><plain>Dev. </plain></SENT>
<SENT sid="674" pm="."><plain>Immunol. 2013 2013 e952469  </plain></SENT>
</text></ref><ref id="B136-cancers-05-01379"><text><SENT sid="675" pm="."><plain>136. LutsiakM.E.SemnaniR.T.de PascalisR.KashmiriS.V.SchlomJ.SabzevariH. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide Blood 2005 105 2862 2868 10.1182/blood-2004-06-2410 15591121 </plain></SENT>
</text></ref><ref id="B137-cancers-05-01379"><text><SENT sid="676" pm="."><plain>137. DannullJ.SuZ.RizzieriD.YangB.K.ColemanD.YanceyD.ZhangA.DahmP.ChaoN.GilboaE. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells J. </plain></SENT>
<SENT sid="677" pm="."><plain>Clin. </plain></SENT>
<SENT sid="678" pm="."><plain>Invest. 2005 115 3623 3633 10.1172/JCI25947 16308572 </plain></SENT>
</text></ref><ref id="B138-cancers-05-01379"><text><SENT sid="679" pm="."><plain>138. MorseM.A.HobeikaA.C.OsadaT.SerraD.NiedzwieckiD.LyerlyH.K.ClayT.M. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines Blood 2008 112 610 618 10.1182/blood-2008-01-135319 18519811 </plain></SENT>
</text></ref><ref id="B139-cancers-05-01379"><text><SENT sid="680" pm="."><plain>139. AttiaP.PowellD.J.Jr.MakerA.V.KreitmanR.J.PastanI.RosenbergS.A. Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2 J. </plain></SENT>
<SENT sid="681" pm="."><plain>Immunother. 2006 29 208 214 10.1097/01.cji.0000187959.45803.0c 16531821 </plain></SENT>
</text></ref><ref id="B140-cancers-05-01379"><text><SENT sid="682" pm="."><plain>140. De RezendeL.C.SilvaI.V.RangelL.B.GuimaraesM.C.  Regulatory T cell as a target for cancer therapy Arch. </plain></SENT>
<SENT sid="683" pm="."><plain>Immunol. </plain></SENT>
<SENT sid="684" pm="."><plain>Ther. </plain></SENT>
<SENT sid="685" pm="."><plain>Exp. </plain></SENT>
<SENT sid="686" pm="."><plain>(Warsz.) 2010 58 179 190 10.1007/s00005-010-0075-0 20373146 </plain></SENT>
</text></ref><ref id="B141-cancers-05-01379"><text><SENT sid="687" pm="."><plain>141. BovenbergM.S.DegelingM.H.TannousB.A. Cell-based immunotherapy against gliomas: From bench to bedside Mol. </plain></SENT>
<SENT sid="688" pm="."><plain>Ther. 2013 21 1297 1305 10.1038/mt.2013.80 23648695 </plain></SENT>
</text></ref><ref id="B142-cancers-05-01379"><text><SENT sid="689" pm="."><plain>142. ChowK.H.GottschalkS. Cellular immunotherapy for high-grade glioma Immunotherapy 2011 3 423 434 10.2217/imt.10.110 21395383 </plain></SENT>
</text></ref><ref id="B143-cancers-05-01379"><text><SENT sid="690" pm="."><plain>143. SchwartzentruberD.J.LawsonD.H.RichardsJ.M.ConryR.M.MillerD.M.TreismanJ.GailaniF.RileyL.ConlonK.PockajB. gp100 Peptide vaccine and interleukin-2 in patients with advanced melanoma N. </plain></SENT>
<SENT sid="691" pm="."><plain>Engl. </plain></SENT>
<SENT sid="692" pm="."><plain>J. </plain></SENT>
<SENT sid="693" pm="."><plain>Med. 2011 364 2119 2127 10.1056/NEJMoa1012863 21631324 </plain></SENT>
</text></ref><ref id="B144-cancers-05-01379"><text><SENT sid="694" pm="."><plain>144. WikstrandC.J.BignerD.D. Immunobiologic aspects of the brain and human gliomas. </plain></SENT>
<SENT sid="695" pm="."><plain>A review Am. </plain></SENT>
<SENT sid="696" pm="."><plain>J. </plain></SENT>
<SENT sid="697" pm="."><plain>Pathol. 1980 98 517 568 6986786 </plain></SENT>
</text></ref><ref id="B145-cancers-05-01379"><text><SENT sid="698" pm="."><plain>145. NellerM.A.LópezJ.A.SchmidtC.W. Antigens for cancer immunotherapy Semin. </plain></SENT>
<SENT sid="699" pm="."><plain>Immunol. 2008 20 286 295 10.1016/j.smim.2008.09.006 18951039 </plain></SENT>
</text></ref><ref id="B146-cancers-05-01379"><text><SENT sid="700" pm="."><plain>146. PrinsR.M.WangX.SotoH.YoungE.LisieroD.N.FongB.EversonR.YongW.H.LaiA.LiG. Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients J. </plain></SENT>
<SENT sid="701" pm="."><plain>Immunother. 2013 36 152 157 10.1097/CJI.0b013e3182811ae4 23377664 </plain></SENT>
</text></ref><ref id="B147-cancers-05-01379"><text><SENT sid="702" pm="."><plain>147. ZhangJ.G.EguchiJ.KruseC.A.GomezG.G.FakhraiH.SchroterS.MaW.HoaN.MinevB.DelgadoC. Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics Clin. </plain></SENT>
<SENT sid="703" pm="."><plain>Cancer Res. 2007 13 566 575 10.1158/1078-0432.CCR-06-1576 17255279 </plain></SENT>
</text></ref><ref id="B148-cancers-05-01379"><text><SENT sid="704" pm="."><plain>148. SloanA.E.DanseyR.ZamoranoL.BargerG.HammC.DiazF.BaynesR.WoodG. Adoptive immunotherapy in patients with recurrent malignant glioma: Preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes Neurosurg. </plain></SENT>
<SENT sid="705" pm="."><plain>Focus 2000 9 e9 16817692 </plain></SENT>
</text></ref><ref id="B149-cancers-05-01379"><text><SENT sid="706" pm="."><plain>149. SchneiderT.GerhardsR.KirchesE.FirschingR. Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme J. </plain></SENT>
<SENT sid="707" pm="."><plain>Neurooncol. 2001 53 39 46 10.1023/A:1011856406683 11678429 </plain></SENT>
</text></ref><ref id="B150-cancers-05-01379"><text><SENT sid="708" pm="."><plain>150. SteinerH.H.BonsantoM.M.BeckhoveP.BryschM.GeletnekyK.AhmadiR.Schuele-FreyerR.KremerP.RanaieG.MatejicD. Antitumor vaccination of patients with glioblastoma multiforme: A pilot study to assess feasibility, safety, and clinical benefit J. </plain></SENT>
<SENT sid="709" pm="."><plain>Clin. </plain></SENT>
<SENT sid="710" pm="."><plain>Oncol. 2004 22 4272 4281 10.1200/JCO.2004.09.038 15452186 </plain></SENT>
</text></ref><ref id="B151-cancers-05-01379"><text><SENT sid="711" pm="."><plain>151. IshikawaE.TsuboiK.YamamotoT.MuroiA.TakanoS.EnomotoT.MatsumuraA.OhnoT. Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients Cancer Sci. 2007 98 1226 1233 10.1111/j.1349-7006.2007.00518.x 17517052 </plain></SENT>
</text></ref><ref id="B152-cancers-05-01379"><text><SENT sid="712" pm="."><plain>152. BanchereauJ.BriereF.CauxC.DavoustJ.LebecqueS.LiuY.J.PulendranB.PaluckaK. Immunobiology of dendritic cells Annu. </plain></SENT>
<SENT sid="713" pm="."><plain>Rev. </plain></SENT>
<SENT sid="714" pm="."><plain>Immunol. 2000 18 767 811 10.1146/annurev.immunol.18.1.767 10837075 </plain></SENT>
</text></ref><ref id="B153-cancers-05-01379"><text><SENT sid="715" pm="."><plain>153. YuJ.S.WheelerC.J.ZeltzerP.M.YingH.FingerD.N.LeeP.K.YongW.H.IncardonaF.ThompsonR.C.RiedingerM.S. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration Cancer Res. 2001 61 842 847 11221866 </plain></SENT>
</text></ref><ref id="B154-cancers-05-01379"><text><SENT sid="716" pm="."><plain>154. LiauL.M.PrinsR.M.KiertscherS.M.OdesaS.K.KremenT.J.GiovannoneA.J.LinJ.W.ChuteD.J.MischelP.S.CloughesyT.F. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment Clin. </plain></SENT>
<SENT sid="717" pm="."><plain>Cancer Res. 2005 11 5515 5525 10.1158/1078-0432.CCR-05-0464 16061868 </plain></SENT>
</text></ref><ref id="B155-cancers-05-01379"><text><SENT sid="718" pm="."><plain>155. YamanakaR.AbeT.YajimaN.TsuchiyaN.HommaJ.KobayashiT.NaritaM.TakahashiM.TanakaR. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: Results of a clinical phase I/II trial Br. </plain></SENT>
<SENT sid="719" pm="."><plain>J. </plain></SENT>
<SENT sid="720" pm="."><plain>Cancer 2003 89 1172 1179 10.1038/sj.bjc.6601268 14520441 </plain></SENT>
</text></ref><ref id="B156-cancers-05-01379"><text><SENT sid="721" pm="."><plain>156. YamanakaR.HommaJ.YajimaN.TsuchiyaN.SanoM.KobayashiT.YoshidaS.AbeT.NaritaM.TakahashiM. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: Results of a clinical phase I/II trial Clin. </plain></SENT>
<SENT sid="722" pm="."><plain>Cancer. </plain></SENT>
<SENT sid="723" pm="."><plain>Res. 2005 11 4160 4167 10.1158/1078-0432.CCR-05-0120 15930352 </plain></SENT>
</text></ref><ref id="B157-cancers-05-01379"><text><SENT sid="724" pm="."><plain>157. WheelerC.J.BlackK.L.LiuG.MazerM.ZhangX.X.PepkowitzS.GoldfingerD.NgH.IrvinD.YuJ.S. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients Cancer Res. 2008 68 5955 5964 10.1158/0008-5472.CAN-07-5973 18632651 </plain></SENT>
</text></ref><ref id="B158-cancers-05-01379"><text><SENT sid="725" pm="."><plain>158. De VleeschouwerS.FieuwsS.RutkowskiS.VanC.F.VanL.J.GoffinJ.SciotR.WilmsG.DemaerelP.Warmuth-MetzM. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme Clin. </plain></SENT>
<SENT sid="726" pm="."><plain>Cancer Res. 2008 14 3098 3104 10.1158/1078-0432.CCR-07-4875 18483377 </plain></SENT>
</text></ref><ref id="B159-cancers-05-01379"><text><SENT sid="727" pm="."><plain>159. ArdonH.van GoolS.LopesI.S.MaesW.SciotR.WilmsG.DemaerelP.BijttebierP.ClaesL.GoffinJ. Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: A pilot study J. </plain></SENT>
<SENT sid="728" pm="."><plain>Neurooncol. 2010 99 261 272 10.1007/s11060-010-0131-y 20146084 </plain></SENT>
</text></ref><ref id="B160-cancers-05-01379"><text><SENT sid="729" pm="."><plain>160. PrinsR.M.SotoH.KonkankitV.OdesaS.K.EskinA.YongW.H.NelsonS.F.LiauL.M. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy Clin. </plain></SENT>
<SENT sid="730" pm="."><plain>Cancer Res. 2011 17 1603 1615 21135147 </plain></SENT>
</text></ref><ref id="B161-cancers-05-01379"><text><SENT sid="731" pm="."><plain>161. FadulC.E.FisherJ.L.HamptonT.H.LallanaE.C.LiZ.GuiJ.SzczepiorkowskiZ.M.TostesonT.D.RhodesC.H.WishartH.A. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy J. </plain></SENT>
<SENT sid="732" pm="."><plain>Immunother. 2011 34 382 389 10.1097/CJI.0b013e318215e300 21499132 </plain></SENT>
</text></ref><ref id="B162-cancers-05-01379"><text><SENT sid="733" pm="."><plain>162. ChoD.Y.YangW.K.LeeH.C.HsuD.M.LinH.L.LinS.Z.ChenC.C.HarnH.J.LiuC.L.LeeW.Y. Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: A phase II clinical trial World Neurosurg. 2012 77 736 744 10.1016/j.wneu.2011.08.020 22120301 </plain></SENT>
</text></ref><ref id="B163-cancers-05-01379"><text><SENT sid="734" pm="."><plain>163. IzumotoS.TsuboiA.OkaY.SuzukiT.HashibaT.KagawaN.HashimotoN.MarunoM.ElisseevaO.A.ShirakataT. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme J. </plain></SENT>
<SENT sid="735" pm="."><plain>Neurosurg. 2008 108 963 971 10.3171/JNS/2008/108/5/0963 18447714 </plain></SENT>
</text></ref><ref id="B164-cancers-05-01379"><text><SENT sid="736" pm="."><plain>164. OttoK.AndersenM.H.EggertA.KeikavoussiP.PedersenL.O.RathJ.C.BockM.BrockerE.B.StratenP.T.KampgenE. Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin Vaccine 2005 23 884 889 10.1016/j.vaccine.2004.08.007 15603888 </plain></SENT>
</text></ref><ref id="B165-cancers-05-01379"><text><SENT sid="737" pm="."><plain>165. UematsuM.OhsawaI.AokageT.NishimakiK.MatsumotoK.TakahashiH.AsohS.TeramotoA.OhtaS. Prognostic significance of the immunohistochemical index of survivin in glioma: A comparative study with the MIB-1 index J. </plain></SENT>
<SENT sid="738" pm="."><plain>Neurooncol. 2005 72 231 238 10.1007/s11060-004-2353-3 15937645 </plain></SENT>
</text></ref><ref id="B166-cancers-05-01379"><text><SENT sid="739" pm="."><plain>166. CiesielskiM.AhluwaliaM.MunichS.OrtonM.BaroneT.Chanan-KhanA.FenstermakerR. Antitumor cytotoxic T-cell response induced by a survivin peptide mimic Cancer Immunol. </plain></SENT>
<SENT sid="740" pm="."><plain>Immunother. 2010 59 1211 1221 10.1007/s00262-010-0845-x 20422411 </plain></SENT>
</text></ref><ref id="B167-cancers-05-01379"><text><SENT sid="741" pm="."><plain>167. HatanpaaK.J.BurmaS.ZhaoD.HabibA.A. Epidermal growth factor receptor in glioma: Signal transduction, neuropathology, imaging, and radioresistance Neoplasia 2010 12 675 684 20824044 </plain></SENT>
</text></ref><ref id="B168-cancers-05-01379"><text><SENT sid="742" pm="."><plain>168. GuptaP.HanS.-Y.Holgado-MadrugaM.MitraS.LiG.NittaR.WongA. Development of an EGFRvIII specific recombinant antibody BMC Biotechnol. 2010 10 e72  </plain></SENT>
</text></ref><ref id="B169-cancers-05-01379"><text><SENT sid="743" pm="."><plain>169. WongA.BignerS.BignerD.KinzlerK.HamiltonS.VogelsteinB. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification Proc. </plain></SENT>
<SENT sid="744" pm="."><plain>Natl. </plain></SENT>
<SENT sid="745" pm="."><plain>Acad. </plain></SENT>
<SENT sid="746" pm="."><plain>Sci. </plain></SENT>
<SENT sid="747" pm="."><plain>USA 1987 84 6899 6903 10.1073/pnas.84.19.6899 3477813 </plain></SENT>
</text></ref><ref id="B170-cancers-05-01379"><text><SENT sid="748" pm="."><plain>170. FriguetB.ChaffotteA.Djavadi-OhanianceL.GoldbergM. Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay J. </plain></SENT>
<SENT sid="749" pm="."><plain>Immunol. </plain></SENT>
<SENT sid="750" pm="."><plain>Methods 1985 77 305 319 10.1016/0022-1759(85)90044-4 3981007 </plain></SENT>
</text></ref><ref id="B171-cancers-05-01379"><text><SENT sid="751" pm="."><plain>171. MukasaA.WykoskyJ.LigonK.ChinL.CaveneeW.FurnariF. Mutant EGFR is required for maintainenece of glioma growth in vivo, and its ablation leads to escape from receptor dependence Proc. </plain></SENT>
<SENT sid="752" pm="."><plain>Natl. </plain></SENT>
<SENT sid="753" pm="."><plain>Acad. </plain></SENT>
<SENT sid="754" pm="."><plain>Sci. </plain></SENT>
<SENT sid="755" pm="."><plain>USA 2010 107 2616 2621 20133782 </plain></SENT>
</text></ref><ref id="B172-cancers-05-01379"><text><SENT sid="756" pm="."><plain>172. HeimbergerA.B.SukiD.YangD.ShiW.AldapeK. The natural history of EGFR and EGFRvIII in glioblastoma patients J. </plain></SENT>
<SENT sid="757" pm="."><plain>Transl. </plain></SENT>
<SENT sid="758" pm="."><plain>Med. 2005 3 e38 10.1186/1479-5876-3-38  </plain></SENT>
</text></ref><ref id="B173-cancers-05-01379"><text><SENT sid="759" pm="."><plain>173. HeimbergerA.B.HlatkyR.SukiD.YangD.WeinbergJ.GilbertM.SawayaR.AldapeK. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients Clin. </plain></SENT>
<SENT sid="760" pm="."><plain>Cancer Res. 2005 11 1462 1466 10.1158/1078-0432.CCR-04-1737 15746047 </plain></SENT>
</text></ref><ref id="B174-cancers-05-01379"><text><SENT sid="761" pm="."><plain>174. SampsonJ.H.HeimbergerA.B.ArcherG.E.AldapeK.D.FriedmanA.H.FriedmanH.S.GilbertM.R.HerndonJ.E.McLendonR.E.MitchellD.A. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma J. </plain></SENT>
<SENT sid="762" pm="."><plain>Clin. </plain></SENT>
<SENT sid="763" pm="."><plain>Oncol. 2010 28 4722 4729 10.1200/JCO.2010.28.6963 20921459 </plain></SENT>
</text></ref><ref id="B175-cancers-05-01379"><text><SENT sid="764" pm="."><plain>175. VanderlugtC.L.MillerS.D. Epitope spreading in immune-mediated diseases: Implications for immunotherapy Nat. </plain></SENT>
<SENT sid="765" pm="."><plain>Rev. </plain></SENT>
<SENT sid="766" pm="."><plain>Immunol. 2002 2 85 95 10.1038/nri724 11910899 </plain></SENT>
</text></ref><ref id="B176-cancers-05-01379"><text><SENT sid="767" pm="."><plain>176. YajimaN.YamanakaR.MineT.TsuchiyaN.HommaJ.SanoM.KuramotoT.ObataY.KomatsuN.ArimaY. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma Clin. </plain></SENT>
<SENT sid="768" pm="."><plain>Cancer Res. 2005 11 5900 5911 10.1158/1078-0432.CCR-05-0559 16115932 </plain></SENT>
</text></ref><ref id="B177-cancers-05-01379"><text><SENT sid="769" pm="."><plain>177. TerasakiM.ShibuiS.NaritaY.FujimakiT.AokiT.KajiwaraK.SawamuraY.KurisuK.MinetaT.YamadaA. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen-A24 with recurrent or progressive glioblastoma multiforme J. </plain></SENT>
<SENT sid="770" pm="."><plain>Clin. </plain></SENT>
<SENT sid="771" pm="."><plain>Oncol. 2011 29 337 344 10.1200/JCO.2010.29.7499 21149665 </plain></SENT>
</text></ref><ref id="B178-cancers-05-01379"><text><SENT sid="772" pm="."><plain>178. PhuphanichS.WheelerC.J.RudnickJ.D.MazerM.WangH.NunoM.A.RichardsonJ.E.FanX.JiJ.ChuR.M. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma Cancer Immunol. </plain></SENT>
<SENT sid="773" pm="."><plain>Immunother. 2012 62 125 135 22847020 </plain></SENT>
</text></ref><ref id="B179-cancers-05-01379"><text><SENT sid="774" pm="."><plain>179. NishimuraF.DusakJ.E.EguchiJ.ZhuX.GambottoA.StorkusW.J.OkadaH. Adoptive transfer of Type 1 CTL mediates effective anti-central nervous system tumor response: Critical roles of IFN-inducible protein-10 Cancer Res. 2006 66 4478 4487 10.1158/0008-5472.CAN-05-3825 16618775 </plain></SENT>
</text></ref><ref id="B180-cancers-05-01379"><text><SENT sid="775" pm="."><plain>180. FujitaM.ZhuX.SasakiK.UedaR.LowK.L.PollackI.F.OkadaH. Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma J. </plain></SENT>
<SENT sid="776" pm="."><plain>Immunol. 2008 180 2089 2098 18250414 </plain></SENT>
</text></ref><ref id="B181-cancers-05-01379"><text><SENT sid="777" pm="."><plain>181. ZhuX.Fallert-JuneckoB.FujitaM.UedaR.KohanbashG.KastenhuberE.McDonaldH.LiuY.KalinskiP.ReinhartT. Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-α and IFN-γ dependent manners Cancer Immunol. </plain></SENT>
<SENT sid="778" pm="."><plain>Immunother. 2010 59 1401 1409 10.1007/s00262-010-0876-3 20549206 </plain></SENT>
</text></ref><ref id="B182-cancers-05-01379"><text><SENT sid="779" pm="."><plain>182. ZhuX.NishimuraF.SasakiK.FujitaM.DusakJ.E.EguchiJ.Fellows-MayleW.StorkusW.J.WalkerP.R.SalazarA.M. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models J. </plain></SENT>
<SENT sid="780" pm="."><plain>Transl. </plain></SENT>
<SENT sid="781" pm="."><plain>Med. 2007 5 e10 10.1186/1479-5876-5-10  </plain></SENT>
</text></ref><ref id="B183-cancers-05-01379"><text><SENT sid="782" pm="."><plain>183. OkadaH.KalinskiP.UedaR.HojiA.KohanbashG.DoneganT.E.MintzA.H.EnghJ.A.BartlettD.L.BrownC.K. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma J. </plain></SENT>
<SENT sid="783" pm="."><plain>Clin. </plain></SENT>
<SENT sid="784" pm="."><plain>Oncol. 2011 29 330 336 10.1200/JCO.2010.30.7744 21149657 </plain></SENT>
</text></ref><ref id="B184-cancers-05-01379"><text><SENT sid="785" pm="."><plain>184. IwamiK.ShimatoS.OhnoM.OkadaH.NakaharaN.SatoY.YoshidaJ.SuzukiS.NishikawaH.ShikuH. Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor alpha2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele Cytotherapy 2012 14 733 742 22424217 </plain></SENT>
</text></ref><ref id="B185-cancers-05-01379"><text><SENT sid="786" pm="."><plain>185. DutoitV.Herold-MendeC.HilfN.SchoorO.BeckhoveP.BucherJ.DorschK.FlohrS.FritscheJ.LewandrowskiP. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy Brain 2012 135 1042 1054 10.1093/brain/aws042 22418738 </plain></SENT>
</text></ref><ref id="B186-cancers-05-01379"><text><SENT sid="787" pm="."><plain>186. ArdonH.de VleeschouwerS.van CalenberghF.ClaesL.KrammC.M.RutkowskiS.WolffJ.E.van GoolS.W. Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours Pediatr. </plain></SENT>
<SENT sid="788" pm="."><plain>Blood Cancer 2010 54 519 525 19852061 </plain></SENT>
</text></ref><ref id="B187-cancers-05-01379"><text><SENT sid="789" pm="."><plain>187. CarusoD.A.OrmeL.M.NealeA.M.RadcliffF.J.AmorG.M.MaixnerW.DownieP.HassallT.E.TangM.L.AshleyD.M. Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer Neuro-oncology 2004 6 236 246 10.1215/S1152851703000668 15279716 </plain></SENT>
</text></ref><ref id="B188-cancers-05-01379"><text><SENT sid="790" pm="."><plain>188. PollackI.F.JakackiR.I.ButterfieldL.H.OkadaH. Results of a pilot study to evaluate the effects of vaccinations with HLA-A2 restricted glioma antigen-peptides in combination with poly-ICLC for children with newly diagnosed malignant brainstem gliomas, non-brainstem high-grade gliomas, or recurrent unresectable gliomas Neuro-oncology 2011 13 34 40  </plain></SENT>
</text></ref><ref id="B189-cancers-05-01379"><text><SENT sid="791" pm="."><plain>189. PollackI.F.JakackiR.I.ButterfieldL.H.OkadaH. Peptide vaccine therapy for childhood gliomas J. </plain></SENT>
<SENT sid="792" pm="."><plain>Neurosurg. 2012 60 113 119  </plain></SENT>
</text></ref><ref id="B190-cancers-05-01379"><text><SENT sid="793" pm="."><plain>190. PrinsR.M.CraftN.BruhnK.W.Khan-FarooqiH.KoyaR.C.StripeckeR.MillerJ.F.LiauL.M. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: Relation to central nervous system antitumor immunity J. </plain></SENT>
<SENT sid="794" pm="."><plain>Immunol. 2006 176 157 164 16365406 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
